BioPacific Conference 2022

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

2022 BioPacific Conference
23rd Annual Conference of CABS
Resilience and Ingenuity
Embracing Opportunities in a New Normal

8:00 AM - 8:00 PM PT on Saturday, Nov 12, 2022

San Mateo Marriott SFO

1770 S Amphlett Blvd, San Mateo, CA 94402

Enhancing your networking experience with
the CABS SMART Connection Platform
(for details see page 1)

BIOPACIFIC CONFERENCE

2022 SPONSORS

Thank You

Diamond Sponsors

HKSTP
apollomics 冠科美博
HanchorBio
BIOSYSTEMS Acro
FOSUN PHARMA 复星医药

10+ Years Platinum Sponsors

KENSON VENTURES
MORRISON FOERSTER

Platinum Sponsors

PORTON ADVANCED
GenScript Make Research Easy
HANHAI BIOLABS
ProMab Biotechnologies, Inc.
L-PARK 江苏无锡（惠山）生命科技产业园
BIOCYTOGEN
ATON

Gold Sponsors

Genentech A Member of the Roche Group
康龙化成 PHARMARON
X-THERMA
Q BAY center | 钱塘中心
BIORTUS
JJLAKE BUSINESS CENTER
K&L GATES

Silver Sponsors

QLSF Biotherapeutics
药明康德 WuXi AppTec
Medicilon
Bellen
Accurus Biosciences
FRONTAGE YOUR DRUG DEVELOPMENT PARTNER
AD Studio
NVIGEN Nano Vision · Life Science
cosmo making scientific sense
UNIVERSITY OF THE PACIFIC
3H Science Essentials Pharmaceutical analysis
SB SinoBiological
ChemShuttle Synthesizing Life
WuXi Biologics Global Solution Provider
BGI
NT NOVOTECH The Asia Pacific CRO
JOINN BIOLOGICS

Exhibitor Sponsors

EUREKA THERAPEUTICS
Novogene Advancing Genomics, Improving Life
TRIBI SCIENCE www.tribioscience.com; Email: info@tribioscience.com
Sanyou Bio Antibody Drug R&D Ask Sanyou Bio
ChemScene Chemical Reagents For Life Science
ACHEMBLOCK Advanced ChemBlocks Inc
BUTTON
KCI 凯斯艾生物 KCI BioTech
NEWOMICS Enabling Precision Medicine
BUCHI
BizGenius
PharmaLegacy Preclinical Specialty Pharmacology Services
PharmaBlock
BIODURO-SUNDIA 保诺-桑迪亚

Media Partners

世易医健 eChinaHealth
Q BAY center | 钱塘中心
OFFER
MYBIO 美柏医健
JJLAKE BUSINESS CENTER
LEAP From Silicon Valley to the World

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

CABS Contact Information

（联系信息）

Mailing Address（邮政地址）

268 Bush Street, #1888

San Francisco, CA 94104, USA

Website（网页地址）

http://www.cabsweb.org

Email（电子邮件信箱）

General information

（一般信息）

Info@CABSweb.org

Membership（会员申请）

Membership@CABSweb.org

Fundraising（募捐）

Fundraising@CABSweb.org

Brochure Design

（会议手册设计）

Xiaojun Li

Brochure Production

（会议手册制作）

2022 BioPacific Organization Committee

2022 BIOPACIFIC CONFERENCE

Resilience and Ingenuity
Embracing Opportunities in a New Normal

TABLE OF CONTENTS

**The official working language of the conference is English*

Launching the CABS Integrated Connection & Partnering System

人群之中，

遇见了你，

匆匆相逢却不识，

转头错过真可惜!

智能连接我和你，

不再错过”几个亿”!

When you step into a large conference, one hopes to interact with someone who shares a common interest. Common interests may include potential collaborations, supportive mentorships, the perfect job opportunity or even the right fit candidate for the job. These interactions or potential opportunities are often lost due to limited time interactions or transparency opportunities at a conference.

CABS has changed the missed opportunities to open opportunities with the newly launched CABS Integrated Partnering System. This allows you the opportunity to connect and interact with peers indefinitely. There are no more missed opportunities, but rather what are the new open opportunities.

Smart Connection System (i.e. check-in system)
Scan the QR code to connect with conference attendees and to access the conference program electronically.

- Smart Connection System is a platform that CABS provides for BioPacific Conference attendees.
- This platform allows you to explore conference attendees and to make connections via email or phone number.
- The system allows you to share your professional profile to hundreds of peers. You have the option to select “Do Not publish my contact info” if you do not want to share your contact information.

Smart Partnering System
Please visit www.cabs-system.com to access the CABS Smart Partnering System.

- Post and manage your company’s **business requirements** and **job openings**;
- Multi-level filtering enables easy and efficient access to other company’s **business requirements**;
- Search and explore **job openings**.

Tutorials for the system are located at www.cabs-system.com/how.
The best quality display is accessed via a computer.

Our Vision

- *To serve as the gateway linking life science professionals & organizations in the U.S. & Pacific Rim Countries*

Our Mission

- *To SERVE life science professionals to promote professional interactions locally and across the Pacific*
- *To FOSTER business opportunities and exchanges in the life science industry between the U.S. and Pacific Rim countries*
- *To PROMOTE public awareness of progress and development in the life sciences industry*
- *To COLLABORATE with other organizations in areas of mutual interest*

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

WHO WE ARE

The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in the San Francisco Bay Area, California. This is the home of Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceuticals such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and 20000 subscribers in the life sciences industry. About 70% of our members have PhD degrees relating to life sciences. A considerable proportion of the members hold senior research and management positions in US-based and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists or investors in the life sciences sector. CABS is the largest and most active Chinese biopharmaceutical association in North America. We organize many activities to promote international collaborations in life sciences and to provide Science & Technology Parks and life sciences companies in Asia Pacific countries with an excellent platform to promote business and to recruit talent. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders.

Welcome

Carrie Wang, MD
President of CABS

Remarks from the President of Chinese American BioPharmaceutical Society (CABS)

Welcome to the 2022 BioPacific Conference, the 23rd annual conference of Chinese American Biopharmaceutical Society (CABS)!

On behalf of CABS, I would like to express our sincere gratitude to all the speakers and sponsors for their support for our organization as well as this conference. Special thanks to Dr. Kate You, our President-Elect and Organizing Committee Chair of the 2022 BioPacific Conference, Dr. Jessica Sun, Vice Chair, members, and volunteers for their passion, dedication, diligence, and hard work that made this conference possible.

The theme for this year's conference reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. From 2020 to now, the COVID-19 pandemic has created unprecedented challenges for public health, societies and economies around the world. The entire biopharma industry has faced many challenges such as decline in investment, shortages of supply, delay of clinical trials, and struggles in executing successful cross border deals. However, the industry has also made remarkable advances in rapid, sensitive diagnostics, and highly efficacious vaccines for COVID-19. Over the past year, there have been many exciting new developments in the life sciences industry. In 2021, the U.S. FDA has approved 50 safe and effective new drugs.

It is our great honor to recognize the extraordinary achievements of Dr. Scott Liu with the 2022 CABS Ken Fong Award in Life Sciences. Dr. Liu is the Founder, Chairman, and CEO of HanchorBio Inc., was one of the global partners of Fosun International Limited, Co-Founder, President, and CEO of Shanghai Henlius Biotech Inc. During his tenure with Henlius, Dr. Liu led over 30 product development initiatives and successfully launched 5 commercial products in China and Europe. We also appreciate Dr. Liu, Fosun and Henlius's continuous support of CABS in the past years and in the future.

For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States. It has been such an honor and privilege to serve as the president and to work with the 2021-2022 CABS Executive Council (EC) and volunteers. Together we have made great strides in serving our members and achieved many accomplishments including:

- Attracted the largest EC & volunteer team of 82 members and advisors. Many of them from other states, Canada and China;
- Relaunched the Career Advisory Network (CAN) program and successfully recruited 19 mentors and 24 mentees;
- Launched the SMART-Partnership platform to give attendees the best experience at the BioPacific Conference;
- Conducted a highly anticipated series of science and other workshops such as Antibody-based drug development, from R&D to commercialization; Taking the pulse of life sciences innovation in a changing world; Executive presence; 2022 Tax law update; BioPacific Toastmasters club open house; and Happy hour for volunteers networking.

We will continue to offer more opportunities for life sciences professionals to learn and network. We really appreciate your kind support to our organization and we hope you enjoy the Conference.

Carrie Wang, MD
President of CABS

Yuying (Kate) You, PhD, JD
Chair of 2022 BioPacific Conference Organizing Committee, President-elect of CABS

Remarks from the Chair of 2022 BioPacific Conference Organizing Committee, President-Elect of CABS

Welcome to 2022 BioPacific Conference! It is my great honor to serve as the Organizing Committee Chair and work with everyone to organize the Conference. This is also the 23rd Annual Conference of Chinese American Biopharmaceutical Society (CABS).

The theme of 2022 BioPacific Conference is "Resilience and Ingenuity - Embracing Opportunities in a New Normal." In the past several years, we witnessed and were ourselves part of the massive battles against the COVID-19 pandemic in addition to many other diseases. Our bio/pharmaceutical community have demonstrated extraordinary determination, ingenuity and tenacity that helped to tame a profound pandemic into an endemic while making breakthroughs on many other fronts. We are glad that some of these exciting stories will be showcased in this Conference.

Our two keynote speakers, Dr. Dan Sutherlin from Genentech and Prof. Yifan Cheng from UCSF, will provide perspectives on Genentech's approach to small molecule drug discovery and on single particle cryo-EM, respectively. Prof. Yibin Kang from Princeton will discuss cancer fitness genes as emerging therapeutic targets. Dr. Jennifer ("Jen") Allen from Amgen will tell us how she, as a medicinal chemist, and her team discovered the recently approved LUMAKRAS® (Sotorasib). Dr. Scott Liu, the 2022 CABS K. Fong Award winner, will give an acceptance speech about the development of a multi-functional Fc-based designer biologics.

Our conference will also feature a fireside chat with two founders of Turning Point Therapeutics, which has been recently acquired by BMS for 4.1 billion dollars. Dr. Peter Li and Dr. Jean Cui will discuss how they steered the company to leverage opportunities and embrace challenges. Dr. Anjali Shukla from FDA will educate us on the FDA Emerging Technology Program. Dr. Amit Mehta from Genentech will discuss his perspective on how to build partnerships in this new normal. We will also have three panel discussions focusing on investment trends, AI in pharma, and the role of incubator/CRO in drug discovery and development.

Furthermore, our conference will feature a special night program ("China Night") this year. This program will be hosted in two virtually connected venues, one in San Mateo Marriott and the other in Shanghai. China Night will showcase the successful partnership between Fosun and Kite on CAR-T therapy, and feature two panel discussions on cross-border partnerships and collaborations between US and China.

Additionally, we are proud to launch the SMART-partnership platform to facilitate the collaborations between entities and connections among attendees. The SMART-partnership platform allows companies to voice their requests for partnership and collaboration and needs of talent hiring.

CABS events, particularly BioPacific Conference, serve as an excellent interactive platform to engage professionals and companies from startup biotechs to global pharmaceutical companies. I would like to take this opportunity to express my deep gratitude to everyone for making this conference possible. First, I thank our 43 esteemed speakers who take time from their busy schedules to share their invaluable perspectives at this conference. Second, I am very grateful to over 40 sponsors of our conference this year. Third, I would like to give special recognition to our fantastic organizing committee and volunteers. They have worked tirelessly for the past months with passion, dedication, and diligence.

Last but definitely not least, I am very grateful to all of you, our attendees of this conference. I appreciate your participation today and support for CABS. I truly wish you a very enjoyable experience from the Conference.

Yuying (Kate) You, PhD, JD
President-elect of CABS

CABS Leadership

Board of Directors

Yang Tian, PhD
Yan Wang, PhD
Alex J. Zhang, PhD, MBA
Cheni Kwok, PhD, CLP
Jiangwen Majeti, PhD, MBA
Alan Hao, PhD
Zhonghua Pei, PhD
Wentao Zhang, PhD
Janet Xiao, PhD, JD
Shichang Miao, PhD
Jing-Shan Hu, PhD
Cheng Liu, PhD
John Wang, PhD

2021-2022 Executive Council

Office of the President
- President: Carrie Wang, MD, VP Preclinical, ARC Medical, Inc.
- President-Elect: Yuying (Kate) You, PhD, JD, Patent Attorney, Morrison Foerster LLP.
- Past President: Yang Tian, PhD, SVP, Ausper Biopharma

Office of Operations (O2)
- Chair: Sihong Zhou, Scientist, Sutro Biopharma, Inc.
- Member: Zhuoting Tan, BS, Associate Scientist, Proteologix; Maggie Zhou, MS, Associate Scientist, Grail, LLC.

Membership (MEM)
- Co-Chair: Weijie Lan, PhD, VP Cell Therapy, Overland Pharmaceuticals
- Co-Chair: Dong Su, Senior Associate Scientist, Gilead Sciences, Inc.
- Advisor: Han Zhang, PhD, Senior Project Manager, Senti Biosciences, Inc.

Public Relations & Communications (PRC)
- Co-Chair: Guanghui Han, PhD, Senior Director, BGI Americas
- Co-Chair: Lu Lu, MS, Senior Business Development Director, WuXi AppTec
- Member: Suping Ren, MS, Lab Manager, Janssen R&D; Grace Lin, MS, Executive Search Consultant, Jiusheng Inc.; Junjun Cheng, PhD, Senior Scientist, Riboscience LLC.
- Advisor: Hesong Han, PhD, postdoc, UC Berkeley

Alliance Management Committee (AMC)
- Co-Chair: Jessica Sun, PhD, Senior Director, Terremoto Biosciences
- Co-Chair: Weixing Chen, MD, MS, President, Gracious Life Foundation
- Member: Xiaojie Chen, PhD, Business Development Manager, TargetMol Chemicals Inc.; Yu Yang, MS, CEO, Hanhai Silicon Valley; Yao Fang, MS, Accounting Grad Student, San Francisco State University; Zhiyong Yang, PhD, Scientist, Genentech, Inc.
- Advisor: Xu Chen, MS, Business Manager, MaxVision; Dong Su, MS, Senior Associate Scientist, Gilead Sciences, Inc.

Science & Technology Committee (STC)
- Co-Chair: Yan Wang, PhD, Director, ChemPartner
- Co-Chair: Xiang Yi, PhD, Senior Scientist, Amgen
- Member: Xuefeng Wang, PhD, Senior Scientist, ASC Therapeutics; Hesong Sun, PhD, VP Product Development and Operations, ARC Medical, Inc.
- Advisor: Ken Zhang, PhD, Director, AssemblyBio

International Collaboration Committee (ICC)
- Co-Chair: Hesong Sun, PhD, VP Product Development and Operations, ARC Medical, Inc.
- Co-Chair: Xi Fang, PhD, Founding Partner, Button
- Advisor: Qiang Gan, PhD, Staff Scientist, Thermo Fisher Scientific Inc.

Business & Career Development Committee (BCD)
- Co-Chair: Liping Meng, PhD, Senior Research Scientist, Gilead Sciences, Inc.
- Co-Chair: Kay Tong, M.A., Head of Quality & Compliance, Sana Biotechnology, Inc.
- Chair of the CAN Program: Danielle Liu, MS, Senior Partner, CGL Consulting Co., Ltd
- Chair of the Entrepreneurship Club Program: Huijun Zhou, PhD, Distinguished Career Fellow, Stanford University
- Member: Ning (Jack) Zhu, MBA, Head of business development and marketing, Analytical Biosciences Limited

Social Life Committee (SLC)
- Co-Chair: Michael Xie, PhD, Technical Sales Representative, Teledyne Technologies Inc.
- Co-Chair: Li Wang, Arcus Biosciences, Inc.
- Advisor: Sihong Zhou, Scientist, Sutro Biopharma, Inc.

Web Master:
Michael Lin, CTO 911 Inc.
Accountant
Yao Long
Graphic Designer
Xiaojun Li

2022 BioPacific Conference Organizing Committee

Yuying (Kate) You, PhD, JD, Chair; President-Elect, CABS; Patent Attorney, Morrison Foerster LLP.

Jessica Sun, PhD, Vice Chair; Senior Director, Terremoto Biosciences

Carrie Wang, MD, President, CABS; VP Preclinical, ARC Medical, Inc.

Alex Zhang, PhD, MBA, Managing Director of Lifespan BioLabs

Xu Chen, MS, Business Manager, MaxVision

Zhiyong Yang, PhD, Scientist, Genentech, Inc.

Yan Wang, PhD, Director, ChemPartner

Hesong Sun, PhD, VP Product Development and Operations, ARC Medical, Inc.

Xi Fang, PhD, Founding Partner, Button

Ella Mengyao Li, PhD, CEO, Hanhai Biolabs

Sihong Zhou, Scientist, Sutro Biopharma, Inc.

Dong Su, Senior Associate Scientist, Gilead Sciences, Inc.

Weijie Lan, PhD, VP Cell Therapy, Overland Pharmaceuticals

Guanghui Han, PhD, Senior Director, BGI Americas

Lu Lu, MS, Senior Business Development Director, WuXi AppTec

Weixing Chen, MD, MS, President, Gracious Life Foundation

Kay Tong, MA, Head of Quality & Compliance, Sana Biotechnology, Inc.

Liping Meng, PhD, Senior Research Scientist, Gilead Sciences, Inc.

Ning (Jack) Zhu, MBA, Head of Business Development and Marketing, Analytical Biosciences Limited

Michael Xie, PhD, Technical Sales Representative, Teledyne Technologies Inc.

Li Wang, Arcus Biosciences, Inc.

Junjun Cheng, PhD, Senior Scientist, Riboscience LLC.

Xiaojie Chen, PhD, Business Development Manager, TargetMol Chemicals Inc.

Yu Yang, MS, CEO, Hanhai Silicon Valley



Xuefeng Wang, PhD, Senior Scientist, ASC Therapeutics

Qiang Gan, PhD, Staff Scientist, Thermo Fisher Scientific Inc.

Liang He, PhD, Postdoc, UCSF

Junxiao Gao, MS, Graduate Student, UCSF

Shu Huang, PhD, Software Engineer, Twist Bioscience

Yiquan Liu, PhD, Senior Scientist, Gilead Sciences, Inc.

Denna Kwang, Associate Scientist, Truebinding, Inc.

Bing (Vivian) Liu, PhD, Lab Director, Novogene

Jennifer Liu, MS, Founder, JYL Pioneer

Yanan Wang, PhD, Associate Director, Ab Studio

Yaqiang Wang, PhD, Principal Scientist, Arrakis Therapeutics

Maggie Zhou, MS, Associate Scientist, Grail, LLC.

Suping Ren, MS, Lab Manager, Janssen R&D

Danielle Liu, MS, Senior Partner, CGL Consulting Co., Ltd

Lifei (Alex) Yang, PhD, Senior Scientist, Vir Biotechnology

Nancy Shi, Board Secretary, Button

Dongdong Liu, PhD, R&D Scientist, Arcus Biosciences

Wenjia Gu, PhD, Scientist

Web Master:
Michael Lin, CTO 911 Inc.
CABS-systems.com
Lingjun (Leroy) Li, Button
Graphic Designer
Xiaojun Li

CABS 2021 Service Awards

Ten-Year Extraordinary Leadership

Recognizing EC members for more than 10 years of service at CABS committees
Award: Lifetime membership and free pass to CABS activities

Yang Tian
Past President
Ausper Biopharma

Carrie Wang
President
ARC Medical Device



Sihong Zhou
Chair of O2
Sutro Biopharma

Liping Meng
BCD Co-Chair
Gilead Sciences

Five-Year Extraordinary Leadership

Recognizing EC members for more than 5 years of service at CABS committees
Award: Five years' membership and free pass to CABS activities

Yuying (Kate) You
President-Elect
Morrison & Foerster



Jessica Sun
Advisor
Terremoto Biosciences

Dong Su
AMC Co-Chair
Gilead Sciences

Huijun Zhou
E-Club Chair
Stanford University

Xu Chen
AMC Advisor
MaxVision Biosciences

Ken Zhang
STC Advisor
AssemblyBio

Three-Year Extraordinary Leadership

Recognizing EC members for more than three years of service at CABS committees
Award: Three years' of membership and free pass to CABS activities

Yan Wang, STC
Guanghui Han, PRC
Kay Tong, BCD
Xiang Yi, STC
Micheal Xie, SLC

Outstanding Service Award

Recognizing EC members serviced in the 2020-2021 term of CABS committees
Award: Two years' of membership and free pass to 2022 BioPacific

Lu Lu, PRC
Suping Ren, PRC
Xuefeng Wang, STC
Danielle Liu, BCD
Ning (Jack) Zhu, BCD
Maggie Zhou, AMC
Zuoting Tan, O2
Ge Lin, PRC
Min Lin, O2

Co-Chair Contribution Award

Contributions in the 2020-2021 term of CABS executive council

Qiang Gan, ICC
Hesong Han, PRC
Li Wang, SLC
Weijie Lan, MEM
Jingwen Tan, PRC
Suzie Wu, AMC

Special Contribution Award

Organization of seminars during the COVID-19 pandemic and medical supply donation campaign in 2021

Xi Fang, ICC
Weixing Chen, AMC

2022 CABS BIOPACIFIC CONFERENCE

AGENDA

Resilience & Ingenuity - Embracing Opportunities in a New Normal

8:00 AM - 8:00 PM PT on Saturday, November 12, 2022

** The official working language of the conference is English*

8:00 AM – 8:50 AM Registration and Networking

8:50 AM – 8:55 AM — **Welcome Remarks (Virtual)**
Yuying (Kate) You, PhD, JD, President-elect of CABS and Organizing Committee Chair of 2022 BioPacific Conference

8:55 AM – 9:00 AM — **State of the Society**
Carrie Wang, MD, President of CABS

Morning Session 1 – Session Chair: Hesong Sun, PhD

9:00 AM – 9:35 AM — **Keynote: Genentech's Approach to Small Molecule Drug Discovery: Perspectives on Challenges and Opportunities**
Dan Sutherlin, PhD, Senior Vice President, Small Molecule Discovery Chemistry, Genentech

9:35 AM – 10:05 AM — **Cancer Fitness Genes: Emerging Therapeutic Targets for Metastatic Cancers**
Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor, Princeton University

10:05 AM-10:15 AM — **CABS K. Fong Award in Life Sciences**
Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures
Awardee: Scott Liu, PhD, Founder and CEO, HanchorBio Inc. (Co-Founder, former CEO, Henlius)

10:15 AM – 10:35 AM — **Navigating New Territory in Immuno-Oncology through the Development of Multi-Functional Fc-Based Designer Biologics**
Scott Liu, PhD, Founder and CEO, HanchorBio Inc. (Co-Founder, former CEO, Henlius)

10:35 AM – 10:50 AM – 1st Coffee Break

Morning Session 2 – Session Chair: Guanghui Han, PhD

10:50 AM – 11:30 AM — **Fireside Chat: The Birth and Growth of Turning Point Therapeutics -- Founders' Perspective**
Moderator: Kenneth Fong, PhD, Chairman, Kenson Ventures
Speakers: Yishan (Peter) Li, PhD, MBA, Co-Founder, Executive Chairman, BlossomHill Therapeutics, Inc.; Co-Founder, CEO and Chairman (10/2013-10/2018), Turning Point Therapeutics, Inc.
J. Jean Cui, PhD, Co-Founder, President/CEO, BlossomHill Therapeutics, Inc.; Co-Founder, CSO (10/2013-1/2020), Director, Turning Point Therapeutics, Inc.

11:30 AM – 12:10 PM — **Panel Discussion: Healthcare Investment Trends and Strategies**
Moderator: Ella Mengyao Li, PhD, CEO, Hanhai Biolabs
Panelists: Orrin Ailloni-Charas, MD, MBA, Founder and Managing Partner, Cura Capital
Neil J. Littman, MSc, Founder, Bioverge Venture
Cheni Kwok, PhD, CLP, Managing Partner & Founder, Linear Dreams LLC

12:10 PM – 1:15 PM – Lunch Break
Noon sessions: "Enabling Solutions for Drug Discovery: from Starting to Approval"

Concurrent Session A (in Room Synergy 1). Chair: Yanan Wang, PhD

12:20 PM – 12:35 PM — **Leveraging Innovative Processes and Manufacturing to Accelerate the Quality Development of Advanced Cell and Gene Therapeutics**
YangZhou Wang, PhD, CEO, Porton Advanced Solutions

12:35 PM --12:45 PM — **End-to-end Drug Discovery Solutions**
Connie Sun, PhD, SVP, Global Head of BD, Small Molecules, Pharmaron

12:45 PM – 12:55 PM — **Pharmaron Clinical – An Integrated Global Clinical Service Platform**
Charles Li, VP, Business Development, Pharmaron

12:55 PM – 1:10 PM — **Selection of Raw Materials for Cell & Gene Therapy**
Tracy Zhao, Senior Field Application Scientist, ACROBiosystems

Concurrent Session B (in Room Synergy 5). Chair: Vivian Liu, PhD

12:20 PM –12:30 PM — **Next-Generation DMSO- & Serum-Free Cryopreservation for Cell Therapy Manufacturing & Pressing**
Xiaoxi Wei, PhD, Co-Founder & CEO, X-Therma

12:30 PM – 12:40 PM — **Accelerating Molecules to Market**
Min Park, MBA, Chief Business Officer, Aton Biotech – A Henlius Company

12:40 PM – 12:50 PM — **Drug Safety: The Concept, Inception, and Its Importance**
Michael Zhao, Q Bay Boston Partner, Q Bay

12:50 PM – 1:00 PM — **A New Era for Biotech Founders**
Jian Jiang, PhD & Linda Zhou, Partners, K&L Gates

1:00 PM – 1:10 PM — **Biortus, from Gene to Lead: Your Partner in Drug Discovery**
Ilean Chai, Associate Director, Business Development, Biortus

Afternoon Session 1 – Session Chair: Zhiyong Yang, PhD

1:15 PM – 1:50 PM — **Keynote: Structural Biology in the Era of Single Particle Cryo-EM**
Yifan Cheng, PhD, Professor, HHMI Investigator, UCSF

1:50 PM –2:20 PM — **A Day in the Life of a Medicinal Chemist – Discovery of Sotorasib**
Jennifer Allen, PhD, Executive Director of Medicinal Chemistry, Amgen

2:20 PM – 2:45 PM — **Panel Discussion: Surviving the Valley of Death in Drug Discovery with the Right Mice in a Good Incubator**
Moderator: Yan Wang, PhD, Director, Peptide Chemistry, ChemPartner
Panelists: James Jin, PhD, Vice President, Biocytogen
Ray Chen, PhD, President of Life Science Group, GenScript
Yifu Liu, Executive Director, JJLake Accelerator

2:45 PM – 3:00 PM – 2nd Coffee Break

Afternoon Session 2 – Session Chair: Xi Fang, PhD

3:00 PM – 3:30 PM — **Emerging Technology Program (Virtual)**
Anjali Shukla, PhD, Team Lead, Office of Biotechnology Products, FDA Center for Drug Evaluation & Research

3:30 PM -- 4:00 PM — **Partnerships to Build Resilience and Accelerate Innovation**
Amit Mehta, PhD, Vice President and the Head of Business Development, Genentech

4:00 PM -- 4:35 PM — **Panel Discussion: AI in Pharma and Life Sciences**
Moderator: Yang Shao, PhD, Director of Production Operations, Curia Bio
Panelists: Michelle Chen, PhD, Chief Business Officer, Insilico Medicine
Abraham Heifets, PhD, CEO, Atomwise
Hogene Choi, JD, Partner, Morrison Foerster LLP

4:35 PM -- 4:40 PM — **Day Program Closing Remarks & Introduction of "China Night" Program**
Jessica Sun, PhD, Vice Chair of Organizing Committee of 2022 BioPacific Conference

4:40 PM – Day Program Adjourned

2022 BioPacific Conference

China Night Agenda

Resilience and Ingenuity
- Embracing Opportunities in a New Normal

Scan QR Code

To join 2022
CABS conference!

Date & Location

US | 5:30 – 8:00 PM, Pacific Time, November 12, 2022

Engage Room and Courtyard, San Mateo Marriott SFO,
San Mateo, CA 94403

China | 9:30 AM – Noon, Beijing Time, November 13, 2022

Fosun Pharma, Building A, Room 209,
1289 Yilan Road, Xuhui District,
Shanghai, PRC

Agenda

(All time PST)

5:30 – 5:45 Welcome Remarks
By Deyong Wen, CEO of Fosun Pharmaceutical

5:45 – 6:00 Conference Remarks
By Dr. Carrie Wang, President of CABS

6:00 – 6:30 Keynote Speech
Cell Therapy Development Trends and the Journey to Commercialization in China

By Yuanyuan Qi, Deputy COO of Fosun Kite

6:30 – 7:15 Panel Discussion I
Accelerating the Globalization by Expanding the Chinese Biopharma Innovation Ecosystem (in Shanghai venue)

Moderator:
Wei Wu, PhD, Senior Director, JJDC
Panelists:
·Guoliang Yu, PhD, Founder and CEO, Apollomics
·Dajun Yang, PhD, Founder, President and CEO, Ascentage Pharma
·Patrick Lu, PhD, Founder, President and CEO, Sirnaomics
·Jason Zhu, PhD, President of Henlius

7:15 – 8:00 Panel Discussion II
The US-Based Biotech Innovations and New Development in Therapeutics (in US venue)

Moderator:
Alex J. Zhang, PhD, Board Member of CABS
Panelists:
·David Sheng, PhD, Founder and CEO, Proteologix
·George Wu, PhD, Founder and CEO, Amberstone Biosciences
·Janice Zang, PhD, Founder and CEO, N1 Life
·Dandan Dong, PhD, Founder and CBO, Arrivent Biopharma

Organizers: CABS 北美华人生物医药协会 · FOSUN PHARMA USA INC.

Supporting Organizers: BayHelix GROUP · HANHAI BIOLABS



2022 BIOPACIFIC CONFERENCE

Floor Plan - San Mateo Marriott

1770 South Amphlett Blvd., San Mateo, CA 94402

- The main conference
- Exhibition
- Lunch Workshop
- Lunch Workshop

The night program will be on Level 1, in Engage Room and the Courtyard.

Conference Floor Plan



Exhibition Floor Table Plan

10 Feet

Note:
- Standard Aisle space is 6' per fire code
- Please follow the angle and position of the tables
- Fire exits must be visible and not blocked
- Diagram is not to scale

Keynote Speaker

Dan Sutherlin, PhD
Senior Vice President, Small Molecule Discovery Chemistry
Genentech
A Member of the Roche Group

Genentech's Approach to Small Molecule Drug Discovery Perspectives on Challenges and Opportunities

Dan Sutherlin is the Senior Vice President of Small Molecule Drug Discovery in Genentech Research and Early Development (gRED). In this role, Dan leads an organization of over 400 scientists in medicinal chemistry, computational chemistry, drug metabolism, pharmaceutics, and biochemical and cellular pharmacology who are focused on the discovery and development of novel drug candidates in multiple therapeutic areas. His organization contributes to the progression of the gRED small molecule portfolio and supports many non-small molecule projects in the portfolio.

Dan earned his Ph.D. from the University of California, Los Angeles with Robert Armstrong in 1996 and completed postdoctoral work with Peter Schultz at the University of California, Berkeley. From 1999, beginning his career at Genentech, Inc., Dan made several contributions to the development pipeline including the marketed hedgehog inhibitor vismodegib. This team effort was recognized by the American Chemical Society through the "Heroes of Chemistry" award in 2018. He has functioned as a Project Team Leader for multiple small molecule discovery projects in research and led a development team for Nav1.7 inhibitors GDC-0276 and GDC-0310 through Phase 1. Dan has contributed to over 80 scientific papers and patents covering Genentech research. He began his current role at gRED in 2021 and prior to that he was the Vice President of Discovery Chemistry from 2018-2021.

Abstract:
The numerous challenges facing drug discovery scientists has been met with an expansion of technologies and approaches that aim to expand the druggable genome and increase the efficiency of drug design and development. In the small-molecule drug discovery group at Genentech, we are exploring many of these advances in our field in the context of a larger gRED strategy. The general philosophy and vision to increase our probability of success for Genentech's drug discovery will be discussed first. Then the application of cryoEM to structure based design, novel approaches to the degradation mechanism of action, and the use of machine learning models in design and synthesis will be shared as examples of the many ways that advanced technologies are expected to contribute to our quest to make a meaningful impact on patients' lives.

Keynote Speaker

Yifan Cheng, PhD
Professor, HHMI Investigator
UCSF

Structural biology in the era of single particle cryo-EM

Yifan Cheng is currently an Investigator at the Howard Hughes Medical Institute and a Professor at Department of Biochemistry and Biophysics, University of California, San Francisco (UCSF). He received his Ph.D. degree in 1991 from the Institute of Physics, Chinese Academy of Sciences (CAS). From 1991 to 1996, he continued his research in solid state physics and electron microscopy as a postdoctoral fellow at University of Oslo (NTNF Fellow) and Max-Planck-Institute of Metal Research (Alexander von Humboldt Fellow). In 1996, he changed his research direction to structural biology, and received further training in cryo-electron microscopy (cryo-EM) from Professors Kenneth Taylor at Florida State University and Yoshinori Fujiyoshi at Kyoto University. In 1999, he joined the laboratory of Thomas Walz to set up a cryo-EM operation at the Harvard Medical School. He joined the faculty of University of California, San Francisco in 2006 and has remained there ever since. In 2015, he became a HHMI Investigator. He was a recipient of various awards including the Christian B. Anfinsen Award from The Protein Society in 2018, elected member of the American Academy of Arts and Science in 2019, and National Academy of Sciences in 2020.

His laboratory uses cryo-EM to study structures of biological macromolecules, particularly integral membrane proteins, and dynamic complexes. The development of cryo-EM methodology for structural biology is a long-lasting interest of his laboratory. Previous works of his laboratory include developments of algorithms to correct electron beam-induced image motion and structural studies of TRP channels. of HeliconTM peptides will be presented, along with lessons learned on building a powerful new modality drug discovery company.

Abstract:
Structural biology has always played an essential role in facilitating structural based drug discovery and development. With the continuous technological advancement in single particle cryo-EM, the landscape of structural biology is being reshaped in an unprecedented way. Here, I will present two recent examples of my laboratory: dissecting structural mechanism of integrin avb8 mediated L-TGF-b activation, and tagging endogenous proteins in HEK cells to enable structural studies of native protein complexes.



Yibin Kang, PhD
Warner-Lambert/Parke-Davis Professor
PRINCETON UNIVERSITY

Cancer Fitness Genes: Emerging Therapeutic Targets for Metastatic Cancers

Yibin Kang is a Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University, a founding member of the Ludwig Institute for Cancer Research Princeton Branch, and an Associate Director of Rutgers Cancer Institute of New Jersey. Dr. Kang graduated with a bachelor's degree from Fudan University in Shanghai in 1995. After completing his graduate study at Duke in 2000 and postdoctoral training with Dr. Joan Massagué at the Memorial Sloan-Kettering Cancer Center, he joined the faculty of Princeton University as an Assistant Professor of Molecular Biology in 2004. He was promoted to Associate Professor with tenure in 2010 and to Endowed Chair Full Professor in 2012. Dr. Kang has served as the President of the Metastasis Research Society (2016-2018), the Chair of the American Association for Cancer Research (AACR) Tumor Microenvironment Working Group (2018-2019), and President of the Chinese Biological Investigator Society (2018-2022).

Dr. Kang's research focuses on the molecular mechanisms of breast cancer metastasis. His work discovered new genes that promote progression, metastasis, immune evasion and treatment resistance of breast cancer; delineated tumor-stromal interactions that are essential for metastatic growth; identified novel regulators of normal and cancerous stem cells; and developed new cancer therapeutic agents. Dr. Kang has published over 200 original articles in leading journals including Science, Cancer Cell, Nature Cell Biology, Nature Cancer and Nature Medicine. Dr. Kang's outstanding achievements have been recognized by many prestigious awards, including an American Cancer Society Research Scholar Award (2005), Department of Defense Era of Hope Scholar Award (2006), the 2011 Vilcek Prize for Creative Promise in Biomedical Sciences (2011), the American Association for Cancer Research (AACR) Award for Outstanding Achievements in Cancer Research (2012), the Fidler Innovation Award from the Metastasis Research Society (2014), the Fuller Albright Award from the American Society for Bone and Mineral Research (2014), and the AACR Outstanding Investigator Award in Breast Cancer Research (2014). Dr. Kang was elected as a Fellow of American Association for the Advancement of Science (AAAS), a Komen Scholar; an inaugural inductee of the Duke Graduate School Few-Glasson Alumni Society in 2016; and was selected as an American Cancer Society Research Professor in 2019.

Firebrand Therapeutics and KayoThera are two biotech start-ups co-founded by Dr. Kang as a co-Founder. The intellectual properties of these two start-ups were developed in his laboratory.

Abstract:
Development of cancer therapeutics has traditionally focused on targeting driver oncogenes. Such an approach is limited by toxicity to normal tissues and treatment resistance. A class of "cancer fitness genes" with crucial roles in metastasis have been identified. Elevated or altered activities of these genes do not directly cause cancer; instead, they relieve the stresses that tumor cells encounter and help them adapt to a changing microenvironment thus facilitating tumor progression and metastasis. Importantly, as normal cells do not experience high levels of stress under physiological conditions, targeting cancer fitness genes is less likely to cause toxicity to non-cancerous tissues. I will use MTDH as an example to summarize the key features and function of cancer fitness genes and discuss their therapeutic potential.

Scott Liu, PhD
Founder and CEO
HanchorBio

Award Speech

Navigating New Territory in Immuno-Oncology through the Development of Multi-Functional Fc-Based Designer Biologics

Scott Liu is the Founder, Chairman, and CEO of HanchorBio Inc., a global biotechnology company pioneering the development of next-generation immunotherapies. As a life-science entrepreneur and successful biotech company-builder, Scott was one of the global partners of Fosun International Limited and the Co-founder, President and CEO of Shanghai Henlius Biotech Inc., a commercial-stage global biopharmaceutical company with the focus on high-quality, affordable, and innovative biologic medicines, listed on Hong Kong Stock Exchange (2696.HK) with a market value of over US$ 1.1 Billion. During his tenure with Henlius, Scott has led multiple product development initiatives (over 30 biosimilars, novel monoclonal antibodies, and bispecific antibodies) and successfully launched 5 commercial monoclonal antibody products in China and Europe.

Scott has over 30 years of experience in managing corporate development, strategic portfolio, equity, cGMP quality operation, and CMC regulatory affairs. He has been instrumental on the development of the Technical Guidelines for the Research, Development and Evaluation of Biosimilars to promote globalization of the biopharmaceutical industry in China. Additionally, he has participated in development of multiple biological medicines, including Orencia® (for rheumatoid arthritis), Vectibix® (for colorectal cancer), Hanlikang® (rituximab biosimilar), Hanquyou®/Zercepac® (trastuzumab biosimilar), Handayuan® (adalimumab biosimilar), Hanbeitai® (bevacizumab biosimilar) and Hansizhuang® (serplulimab, novel anti-PD1).

Prior to founding HanchorBio and Henlius, Scott has previously served several executive positions such Vice President of Scientific Affairs at United Biomedical Inc., the Founding Director of the Biologics Quality Control Department at Bristol-Myers Squibb (Syracuse, USA), and the Director of Quality Analytical Laboratories at Amgen (Fremont, USA). Scott has authored or co-authored multiple scientific papers and has been an invited speakers in conferences with topics ranging from Biologics Process Development, Biomanufacturing, Oncology Biologics and Immuno-Oncology. He received his Ph.D. in biology at Purdue University and completed his post-doctoral training at Stanford University.

Abstract:
The 2018 Nobel Prize was awarded for the discovery of immune-checkpoint pathways, leading to the revolution of onco-immunotherapies. Ever since the approval of several immune-checkpoint inhibitor (ICI) drugs, including anti-PD-1/PD-L1/CTLA4 antibodies, onco-immunotherapy has provided a new breakthrough treatment for several types of malignant diseases. However, the use of ICIs has proven largely ineffective nowadays in advance malignancies. A combination of low tumor antigenicity, deficits in immune activation along with an exclusive and suppressive tumor microenvironment result in resistance to host defensives. A deepening understanding of these immune escape and suppressive mechanisms has led to the discovery of treatment strategies that may hold the key to a long-awaited therapeutic breakthrough. Blockade of ligand binding to extracellular receptors through traditional neutralizing antibodies has been widely used as an anti-cancer treatment strategy. Herein, HanchorBio has chosen the ligand traps, also known as receptor decoys, strategy by developing a fusion protein which mimic the natural receptor/ligand binding and effectively block multiple ligands. Our proprietary Fc-based-designer biologics (FBDBTM) platform enables biologics with diverse multi-targeting modalities to simultaneously overcome several mechanisms. Furthermore, our preliminary in-vivo data has demonstrated the potential superiority of such FBDBTM molecules than the current immunotherapy agents, highlighting the importance of next-generation immunotherapies.

Amit Mehta, PhD
Vice President
Genentech

Partnerships to Build Resilience and Accelerate Innovation

Amit Mehta is Vice President and the Head of Business Development at Genentech, Inc. His group is responsible for sourcing novel science as well as leading and/or executing partnering transactions in support of Genentech's internal research and therapeutic area strategies. Amit joined the Business Development team in 2015 and over the years has played an instrumental role in establishing several external partnerships across research platforms, personalized health care, neuroscience, and ophthalmology. Prior to joining Business Development, he held positions of increasing responsibilities in Pharma Technical Development including leadership of several early and late-stage programs and chairing the Bispecific Portfolio Steering Committee. Amit holds a Ph.D. in Chemical Engineering from the Pennsylvania State University.

Abstract:
Dr. Mehta will provide an overview of Genentech's approach to accessing external innovation, strategic focus areas, and recent partnerships. He will also share his thoughts on the current macroeconomic climate, trends in public and private financing, and how Genentech continues to thoughtfully invest amidst this turbulence to accelerate innovation and shape the future of medicine and healthcare.

Jennifer Allen, PhD
Executive Director
AMGEN®

A Day in the life of a Medicinal Chemist – Discovery of Sotorasib

Jennifer Allen is currently Executive Director of Research at Amgen in Thousand Oaks, California and leading the global Amgen Medicinal Chemistry team. She has a B.S. in Chemistry from Miami University (Oxford, OH), Ph.D. in Organic Chemistry from Duke University under the guidance of Professor Ned A. Porter, and completed a NIH postdoctoral fellowship with Professor Samuel J. Danishefsky at Memorial Sloan Kettering Cancer Center. After her postdoctoral work, she spent five years as a medicinal chemist at Eli Lilly before moving to Amgen almost 18 years ago. At Amgen, Dr. Allen has contributed to over 15 preclinical candidate nominations across multiple therapeutic areas including oncology, metabolic disorders and neuroscience. She is a co-inventor on over 35 patents and co-author on over 35 scientific manuscripts, including Amgen's most recently launched small molecule therapeutic LUMAKRASTM . She believes that diversity, equity and inclusion are critical components to high-quality science.

Abstract:
KRAS is one of the most frequently mutated oncogenes in human cancer. Despite more than three decades of research, indirect approaches targeting KRAS-mutant cancers have largely failed to show clinical benefit, and direct approaches have been stymied by the apparently 'undruggable' nature of KRAS. I'll describe efforts at Amgen to identify cysteine-reactive molecules capable of selectively inhibiting a prevalent KRAS mutation, KRASG12C. These efforts leveraged iterative screening and structural biology studies, property-based optimization, and careful process engineering to ultimately deliver a highly potent, selective, and well-tolerated inhibitor of KRASG12C: LUMAKRAS® (sotorasib).

Anjali Shukla, PhD
Emerging Technology Team
Food and Drug Administration (FDA)

Emerging Technology Program

Anjali Shukla is a member of the Emerging Technology Team of FDA's Emerging Technology Program and a Team Lead in the Office of Biotechnology Products, CDER, FDA with a focus on chemistry, manufacturing, and control programs of biotechnology products at all stages of drug development. Anjali serves as a CMC subject matter expert for insulin products, FDA liaison to the United States Pharmacopeia, and leads a product quality assessment team for biologic products, including biosimilars. She also performs FDA pre-license inspections of drug manufacturing facilities. Anjali has been the recipient of several awards for her work at the FDA. Prior to joining the FDA, Anjali was a Staff Scientist in the Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH. Anjali received her postdoctoral training also at the NCI.

Abstract:
The FDA Emerging Technology Program (ETP) is a collaborative program where industry representatives can meet with members of the Emerging Technology Team to discuss, identify and resolve potential technical and regulatory issues regarding the developments and implementation of a novel technology prior to filing a regulatory submission. This talk will describe how the ETP encourages and supports the adoption of innovative technology to modernize pharmaceutical development and manufacturing through close collaboration with industry and other relevant stakeholders. Additionally, examples of some of the emerging technologies and information on how to apply to the ETP will be discussed.

Fireside Chat

The Birth and Growth of Turning Point Therapeutics – Founders' Perspective

Turning Point Therapeutics is a San Diego based oncology drug company co-founded by a Chinese American power-couple, Dr. Yishan (Peter) Li and Dr. Jingrong (Jean) Cui. Under their leadership, the company was successfully acquired by Bristol Myers Squibb for $4.1 billion earlier this year. Dr. Li was the Chairman and CEO of Turning Point Therapeutics and guided the company to a successful $191 million IPO on NASDAQ within 5 years of founding. Dr. Cui, as the CSO, combined the company's deep understanding of tumor biology with its industry-leading expertise in structure-based drug design. The result was a rich pipeline of revolutionary clinical-stage oncology drug candidates to precisely target key cancer signaling pathways. Dr. Jean Cui and Dr. Peter Li will share their story of this amazing success.

Fireside Chat Moderator

Kenneth Fong, PhD
Founder and Chairman

KENSON VENTURES

Kenneth Fong is currently the founder and chairman of Kenson Ventures, LLC, a company that specializes in investing and cultivating the growth of biomedical companies. Throughout the last 20 years, a number of companies have been acquired or went public.

Prior to establishing Kenson, Ken was the pioneer in the biomedical industry, having founded and served as CEO of Clontech Laboratories (1984 - 1999), which was acquired by Becton, Dickinson in 1999. Clontech, a leader in the molecular genetics/cell biology market, was also the largest of its kind founded by an Asian American. Clontech had 400 employees, including 65 scientists before its BD acquisition.

Ken has held a number of leadership positions over the years. He served as the president of the Society of Chinese Bioscientists in North America (ca 2,000 members, 2005-2006) and President of the Bay Area AAMA (1987). He was also a member of the Board of Trustees of California State University (2006-2013), the Advisory Board of the College of Science and Engineering at San Francisco State University, Board of Associates at the Whitehead Biomedical Institute at MIT, Board member of UCSD China Center (2018-present) and a Regional Chair and board member of the Committee of 100 (US 2016-2022).

Ken has many other philanthropic interests. He was one of the lead supporters for the San Jose Tech Museum, the Chinese Historical Society in San Francisco, the Bioengineering Auditorium at UC San Diego and the Indiana University graduate Seminar Programs. He has provided a number of scholarships to San Francisco State University, Peking University and the CSU students (Kenneth Fong - Hearst endowed Scholarships). He has established a Translational Research Award program at San Francisco State University (2016-present), an annual CABS K. Fong Award to the Best Biotech Entrepreneurs of the year (2015-present) in addition to the establishment of the Fong Optometry and Medical Library at UC Berkeley (2002), a research grant to the Stanford Eye Institute (2019) and an endowed professorship to Stanford University (2012).

Yishan (Peter) Li, PhD, MBA
Co-Founder and Executive Chairman

BLOSSOMHILL THERAPEUTICS, INC.

Yishan (Peter) Li is Co-Founder and Executive Chairman of BlossomHill Therapeutics, Inc. Dr. Li is also a Co-Founder of Turning Point Therapeutics, Inc., a clinical-stage biotech company, listed on NASDAQ (TPTX). In August 2022, Turning Point was acquired by Bristol Myers Squibb for $4.1 billion. Dr. Li served as Chairman and CEO of Turning Point from October 2013 (founding) to September 2018 and continued to serve as a Director until Turning Point completed a successful $191 million IPO on Nasdaq in April 2019. As Chairman and CEO, Dr. Li led Turning Point for 5 years and successfully raised a total of $147 million in venture financing over 4 rounds from leading biotech investors, such as Cormorant Asset Management, OrbiMed, S.R. One, Lilly Asia Ventures, Foresite Capital, venBio, HBM Partners, Nextech Invest, etc. Under the leadership of Drs. Li and J. Jean Cui, Turning Point rapidly built a strong pipeline with the lead compound Repotrectinib entering a pivotal Phase 2 clinical trial and two additional projects in clinical development (TPX-0022, TPX-0046).

Prior to TP, Dr. Li served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics (acquired by Abcam, March 2012). At Epitomics, Dr. Li successfully built its reagent business from scratch and oversaw all aspects of this business line which included R&D, manufacturing, and marketing/sales. Prior to Epitomics, Dr. Li was Vice President at Kenson Ventures, LLC. He served on the Board of Directors and observers to the Board for biotech companies. Prior to Kenson Ventures, Dr. Li worked in biotechnology corporate finance at investment bank RBC Capital Markets as a summer associate.

Dr. Li was a postdoctoral research fellow at the Department of Molecular and Cell Biology, University of California, Berkeley. He also earned his M.B.A. from Haas School of Business, University of California, Berkeley. He received his Ph.D. in biochemistry from Ohio State University, where he was a University Presidential Fellow, and his B.S. from University of Science and Technology of China.



J. Jean Cui, PhD
Co-Founder, President/CEO

BLOSSOMHILL THERAPEUTICS, INC.

J. Jean Cui is an internationally renowned oncology drug designer with more than 28 years of experience in drug discovery and project management at various major pharmaceutical and biotech companies. Dr. Cui is the lead inventor of Pfizer's precision oncology medicine, Crizotinib (XalkoriTM). She created this drug's novel chemical scaffold based on co-crystal structure, and its final clinical compound. Crizotinib gained fast-track approval from the FDA in 2011 for ALK-positive late-stage non-small cell lung cancer (NSCLC). After Crizotinib, Dr, Cui designed the next-generation ALK medicine Lorlatinib (LORBRENATM) for fighting treatment resistance from the first generation ALK medicine. Dr. Cui also worked on several other oncology projects at Pfizer, including the FDA-approved therapy SUTENTTM.

Dr. Cui is the scientific founder of Turning Point Therapeutics, Inc. focusing on the design and development of novel medicines for cancer patients. At Turning Point, Dr. Cui created 4 clinical compounds for addressing cancer resistance with the leading compound Repotrectinib; achieving 3 FDA Breakthrough Therapy designations, 3 FDA Fast-Track designations, and 1 FDA Orphan Drug Designation to date. Turning Point went public on NASDAQ in April 2019 (TPTX). Dr. Cui served Turning Point's Chief Scientific Officer (October 2013-January 2020) and a member of Board of Directors (October 2013-June 2020). In August 2022, Bristol Myers Squibb acquired Turning Point Therapeutics for $4.1 billion.

Dr. Cui currently is the scientific founder, President, and Chief Executive Officer at BlossomHill Therapeutics, Inc. (July 2020-present). Prior to Turning Point, Dr. Cui was Senior Principal Scientist and then Associate Research Fellow at Pfizer (2003-2013). Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation (1999-2003).

Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011. Dr. Cui was an honoree for two American Chemical Society's Heroes of Chemistry Awards for the discovery and development of Crizotinib and Lorlatinib in 2013 and 2021, respectively. She received two Pfizer Worldwide R&D Achievement Awards (2006 and 2012), and Pfizer Innovation Award in 2011. Dr. Cui received the 2022 Distinguished Alumni Achievement Award from her Ph.D. alma mater, Ohio State University. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013.

Dr. J. Jean Cui received her Ph.D. in Organic Chemistry from Ohio State University in 1994, and her M.S. and B.S. from University of Science and Technology of China. She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California, Berkeley. Dr. Cui started her drug discovery career in biotech and pharmaceutical industries in 1995.

Panel Discussion

Healthcare Investment Trends and Strategy

This panel discusses about healthcare innovations from investor and strategist's perspective. Panelists will talk about their own investment approach and/or strategic considerations, the challenge and hurdle they've ever had during their career, their thought on the most promising healthcare trend in next 10 years and advice giving to startup companies.

Moderator

Ella Mengyao Li, PhD
CEO

HANHAI BIOLABS

Dr. Ella Li, the CEO of Hanhai BioLabs, leads the team in life science investment and globalization to transform healthcare. She is also a venture partner of Network VC, focusing on seed to series A investment in the healthcare sector. She is also the founder of M7 Healthcare Accelerator, providing acceleration, funding, and key resources to healthcare startups. Dr. Li is the former CEO of ZGC Capital and the partner of its U.S. funds. She has established and managed several VC and fund of funds; including one with portfolio funds including KPCB, Menlo, Andreessen Horowitz, Accel, Foundation Capital, and IVP. Dr. Li has over 10 years of experience in biotech research and has rich experiences in therapeutic investment opportunities from discovery and clinical proof-of-concept to commercialization. She also serves as a board advisor, consultant, and advisor for several global accelerators, venture capitalists, and startups. Dr. Ella Li earned her B.S. and M.S. degrees from Peking University, and her Ph.D. from the University of Texas Health Science Centers. She completed her postdoctoral fellowship from Harvard Medical School, where she led five independent projects exploring novel therapeutic targets for metabolic disease. Dr. Li has extensive publications in over 10 prestigious journals with IMF some of which include Nature Communication, Cell Metabolism, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences (PNAS), Molecular Cell, and Diabetes.

Orrin Ailloni-Charas, MD, MBA
Founder and Managing Partner

Cura Capital
INVESTING WITH CARE

Orrin Ailloni-Charas is a physician, entrepreneur, and venture capitalist. As a result of this unique background, he is able to speak about cutting edge medical breakthroughs from both a clinical and business perspective, differentiating important innovations from the hype. Working at the forefront of medical innovation, he has seen time and again that transformation in healthcare can only be achieved when startups solve meaningful clinical problems, have sound core businesses and teams, and coherent capital strategies that account for microeconomic and macroeconomic changes in the near and medium term. As a frequent speaker and pitch competition judge, Orrin is known for his ability to take complex clinical and business concepts and communicate them clearly to a diverse audience.

Orrin is the Founder and Managing Partner of Cura Capital, a San Francisco-based venture capital firm that invests and supports early-stage companies in the Digital Health and MedTech sectors. Prior to that, he was the Managing Partner at the Global Health Impact Fund, a venture fund with a physician-LP network. Orrin began his journey in venture capital and entrepreneurship at AngelMD, leading the Clinical and Investment team in developing an evaluation platform and funding process for healthcare startups and building a large network of physician-experts to support due diligence and investment. Following that, he worked at RedCrow as Managing Director where he created a comprehensive, qualitative, and quantitative analytical platform for evaluating startups. He also produced and hosted a web-based show in partnership with NASDAQ focused on healthcare startups and partnered with the AMA to develop and promote an innovation portal for their Physician Innovation Network.

Orrin is an honors graduate of the University of Pennsylvania. He earned his MD at the NYU School of Medicine and MBA from Columbia University. He completed his residency as a specialist in anesthesia at the Mount Sinai Hospital in New York City. He is a Board Certified Anesthesiologist and served from 2003-2016 as the Chief Financial Officer and Executive Board member of a large private anesthesia practice in San Francisco.

Dr. Ailloni-Charas draws on his experience of 30 years in the clinical practice of anesthesia at top medical institutions as well as lessons learned from 7 years of venture investing and as a physician network builder in the early and mid-stage healthcare vertical.

Cheni Kwok, PhD
Managing Partner and Founder

Linear Dreams LLC | 直梦

Cheni Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 200 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm's engagements include a broad range of business and corporate development activities including managing business development teams, product and technology licensing, search & evaluation of products and technology platforms, merger & acquisitions, corporate strategy, portfolio planning, market and competitive intelligence, due diligence support for financing as well as valuation services for over 60 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan, Korea, and Singapore.

Previously, as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).

Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK; a Ph.D. in human molecular genetics from the University of Cambridge, UK; and has earned a Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS).

Neil J. Littman, M.Sc.
Founder

BIOVERGE

Neil J. Littman, M.S. is the Founder and Managing Director at Bioverge, Inc., a venture capital firm exclusively dedicated to investing in early-stage, cutting-edge healthcare companies. Neil is primarily interested in precision-medicine companies at the intersection of biology and technology that are utilizing advances in technology to modernize healthcare, from bench-to-bedside. Previously, Neil was Vice President of Business Development at Notable Labs, an oncology focused startup and Bioverge portfolio company, where he led the development of global corporate partnerships and contributed to the strategic vision of Notable as part of the Senior Leadership Team. Neil oversaw business development at Notable through the successful completion of the company's $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets.

Previously, Neil was a member of the Executive Leadership Team and Director of Business Development at the California Institute for Regenerative Medicine (CIRM). As part of CIRM's leadership team, Neil helped develop the five-year strategic plan for managing and deploying CIRM's $3 billion across the organization's discovery, translational, and clinical stage stem cell and regenerative medicines programs. Neil was responsible for establishing collaborations with industry partners and investors to accelerate the development of CIRM-funded.

Panel Discussion

Surviving the Valley of Death in Drug Discovery with the Right Mice in a Good Incubator

Please join us for the panel discussion on the role of incubator/ CRO in the drug discovery and development field. How do they balance the investment cost in innovation/new technology and revenue? Beyond the revenue, what are the other things they want to get when working with different clients? Finally, what are their suggestions for young professionals' career path between big Pharma and incubator/CRO?

Moderator

Yan Wang, PhD
Director, Peptide Chemistry

ChemPartner
Dedicated to LifeScience

Yan Wang received her Ph.D. in Organic Chemistry at The Hebrew University of Jerusalem. Then she continued her postdoctoral training at University of California at Davis and at Stanford University.

She is the Director of Peptide Chemistry at ChemPartner-USA and leads a production team of thirty chemists in China.

She has more than fifteen years of experience in medicinal peptide chemistry and has worked on various biological targets, such as GPCRs, kinases, PPI, bacteria, and viruses. She is also an expert in solid/solution phase peptide synthesis, peptide purification, peptide modification, and conjugation.

Ray Chen, PhD
President of Life Science Group

GenScript
Make Research Easy

Ray Chen is President of Life Science Group of GenScript Biotech Corporation, the world leading enabling platform in serving science by providing reliable, high quality and innovative reagents and instruments. Dr. Chen studied peptide chemistry in Dr. Richard DiMarchi laboratory and earned his Ph.D. in Chemistry from Indiana University Bloomington and B.S. in Chemistry from Nanjing University.

James Jin, PhD
Vice President

BIOCYTOGEN

James Jin received his Ph.D. in Virology at Wuhan University in 1997. After his postdoctoral training at Colorado State University, he worked as a Research Assistant Professor at the University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a Senior Scientist. Dr. Jin joined Biocytogen Pharmaceuticals (Beijing) Co., Ltd. as the Director of Technology in 2011, where he was promoted to vice president. His research expertise spans the fields of virology, immunology, proteomics, protein structure, human stem cell, and genetic engineering.

Yifu Liu
Executive Director

JJLAKE
BUSINESS CENTER

Yifu Liu is the Executive Director at JJLake, the U.S.-China cross-border accelerator backed by Oriza Holdings. He has successfully built the brand of JJLake from scratch and accumulated 16000+ subscribers in the last three years. Currently, JJLake has become one of the most renowned cross-border accelerators in the U.S. and has helped over 230 startup founders with global visions. Under his guidance and leadership in accelerating startups, 57 of these companies topped the program by receiving $300M+ resources and successful teams have raised $30M+ funding from Oriza. Before JJLake, he was the co-founder and Business Development at SVC Venture Club (Merged with HYSTA in 2017), pioneering building U.S.-China investor networks. Yifu received his Master's degree in Finance at Hult International Business School.

Panel Discussion

AI in Pharma and Life Sciences

Applying AI to big data in life sciences can help pharmaceutical and life sciences companies reshape business models, streamline biopharma manufacturing, and enhance everything from cognitive molecule research and clinical trial data flow, to self-healing supply chain applications and product intelligence. Three global experts and business executives will join the panel session and share the insights on challenges and opportunities in applying AI to the Life Sciences innovation.

Moderator

Yang Shao, PhD
Director of Production Operations

curia

Yang Shao received his Ph.D. in chemistry from Harvard University and has been in the Bay Area biomedical industry for over 25 years, working for companies like Vector Labs, LakePharma and Curia Bio. He is also a city councilmember of a Silicon Valley City—Fremont.

Abraham Heifets, PhD
CEO

Atomwise

Abraham Heifets is the co-founder and CEO of Atomwise Inc., a leader in Artificial Intelligence Drug Discovery (AIDD) .

Dr. Heifets received his Bachelor and Master degrees in computer science from Cornell University, where he worked on classical artificial intelligence. He received his Ph.D. degree from University of Toronto and was a Massey Fellow and a Fellow of the Ontario Brain Institute where he worked on machine learning to help plan organic syntheses, a long-standing challenge in medicinal chemistry. Before Atomwise Inc., Dr. Heifets researched high-performance data processing at IBM's T.J. Watson Research Center and contributed to the artificial intelligence system of the world-champion robotic soccer team at Cornell University.

Dr. Heifets is an author of 19 publications, patents, and patent applications. He has presented his work at the National Institutes of Health (NIH), the American Chemical Society (ACS), the Association for the Advancement of Artificial Intelligence (AAAI), and the BayHelix conference.

Michelle Chen, PhD
Chief Business Officer

Insilico Medicine

Michelle Chen is the Chief Business Officer of Insilico Medicine, responsible for company corporate and business development, portfolio strategy and marketing. She brings in more than 20 years of extensive experience in both biopharma and technology industries. Prior to Insilico Medicine, she was the Senior Vice President of Corporate Development and Discovery Business Development for WuXi Biologics where she led multiple M&A and licensing transactions; drove strategic partnerships and joint ventures with external biopharma partners; set up a new company in Europe; and fostered investor relations in the United States and Europe. As a biotech executive, Dr. Chen has worked at top pharmaceutical companies such as Roche Group, Merck & Co., and BioMarin Pharmaceutical Inc., as well as biotech and technology companies in roles ranging from business and corporate development, product marketing, and R&D with a strong track record of success. She has a Ph.D. in Biochemistry from the University of Washington, performed her postdoctoral work at the University of California, San Francisco, and received Bioinformatics training at Stanford University.

Hogene Choi, JD
Partner

MORRISON FOERSTER

Hogene Choi works with clients at the forefront of the life sciences, healthcare, and technology industries on a range of intellectual property matters, focusing on patent prosecution, transactions, and counseling.

Hogene develops and manages global patent portfolios for clients ranging from startups to large public companies. She works closely with her clients to understand their business objectives and develop strategies to protect and defend their intellectual property throughout the product life cycle. Her patent prosecution and transaction experience covers technologies related to machine learning, artificial intelligence, bioinformatics, blockchain, computer vision, cloud infrastructure and services, internet applications, server-side architecture, desktop applications and operating systems, graphics, audio/video, semiconductors, medical devices, electronics, nanotechnology, and the mechanical arts.

She also has extensive due diligence experience and regularly advises clients on patent procurement transactions, licensing, and acquisitions. She provides counsel on patentability and freedom-to-operate issues as well as patent portfolio evaluations for business transactions.

Noon Session Speakers

End-to-end Drug Discovery Solutions

Connie Sun, PhD
Senior Vice President

康龙化成 PHARMARON

End-to-end Drug Discovery Solutions

Connie Sun is Senior Vice President, Global Head of Business Development, Small Molecules at Pharmaron. She is responsible for cross-functional business development and partnership alliance management.

Prior to joining Pharmaron, she has 16 years of drug discovery and development experience at biotech and pharma companies. She is author of 35 publications and inventor of 47 patents and is an inventor of Sutent®, which is marketed by Pfizer. She previously held positions as Senior Director of Chemistry at Poniard Pharmaceuticals, Senior Director at AGY Therapeutics Inc. and Director of Chemistry at Pfizer (SUGEN).

Connie holds a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill, North Carolina. Her postdoc training was at Parke-Davis, Warner-Lambert (later Pfizer), Ann Arbor, MI.

Abstract:
Pharmaron's integrated drug discovery services team leads small molecule projects from hit identification to candidate selection. We combine world-class scientific expertise and project leadership with global resources to offer integrated end-to-end support for drug discovery and development. Integrated services provide scientific excellence on par with efficient delivery. We offer solutions to our partners in a timely, cost-effective and sustainable way.

Charles Li
VP, Business Development

康龙化成 PHARMARON

Pharmaron Clinical – An integrated global clinical service platform

Charles Li has over twenty years of working experience in drug research and development, possessing broad life science expertise including medicinal chemistry, radiochemistry, molecular imaging/diagnostics, protein therapeutics, and cell therapies for cancer and neurodegenerative diseases, ranging from discovery, translational to clinical development. Charles was a research scientist before his business profession, playing a variety of leadership roles in different organizations, both in the US and China, focusing on business growth strategy and market validation/penetration. Charles has led business development (sales and marketing) for multiple emerging biotechs and CROs for their critical global growth and is the driver of team building and resource-acquiring. Charles has actively played soccer for thirty years and an intelligent team player.

Abstract:
Pharmaron's integrated platform of global clinical services provides a one-stop shop for our sponsors from both US and China. Our world stand team has a wealth of experience across a wide range of therapeutic areas and our team is proficient in design, conduct and oversight global trials from First In Human to NDA and BLA with full compliance with authorities. Our capabilities include biometrics, regulatory affairs, medical affairs, clinical operations, pharmacovigilance, bioanalytical lab testing.

Michael Zhao
Q Bay Boston Partner

Q BAY center | 钱塘中心

Drug Safety: The concept, Inception, and Its Importance

Michael Zhao started Longwood Biology Inc with friends after graduating from Harvard Medical School, aiming to develop effective and low toxic anti-neurodegenerative drugs from small molecules, and translating bench work to bedside therapies for Alzheimer's disease. He founded LB Ventures in 2016 for early-stage startups in the biotech industry. LB Ventures invests globally across the spectrum of healthcare companies including pharmaceuticals, medical devices, and medical services, focusing on developing and expanding early-stage life science and technology companies with strong potential to achieve global success in their markets. In 2017 he established the team of HLT Inc with friends which is a medical analytics company focused on analytical solutions, pharmaceutical market access and real world evidence through a better use of AI technology, data acquisition and analytics. In 2020, he joined Q Bay as a partner focusing on the platform to support innovation and connect entrepreneurs. Q Bay is committed to accelerating start-up development by leveraging technology resources and finance accessibility, while building a diverse community.

Abstract:
The drug safety concept has earned a lot of attention during the past decade due to the fact it plays a major role in patients' health. It is one of the hottest topics in daily medical practice, particularly with regard to approving new medication or questioning the possibility of withdrawing a drug from the market. Drug safety monitoring and risk management are vitally important for medicinal product developers, license holders, and clinical investigators. In addition to their duty to protect public health, increasingly tight regulation and potentially massive payments to litigants provide strong incentives for pharmaceutical and biotechnology companies to ensure that they maintain efficient systems for drug safety and good pharmacovigilance practice.

Min Park
Chief Business Officer

ATON

SMART STRATEGIES: Accelerate Molecule to Market

Min Park is the Chief Business Officer at Aton Biotech – A Henlius Company, responsible for establishing long-term growth strategy for the company. He has over 20 years of domestic and international experience in developing, implementing, and managing global commercial operations in the life science industry. He successfully launched several CDMOs from Biologics to Cell and Gene Therapy with aggressive targets. Prior, he has served at WuXi AppTec - WuXi Advanced Therapies, Abzena, Catalent, Samsung Biologics, and several other CDMO holding several global leadership roles. He is also a Vice Chairman of the Board with National Association of Asian American Professionals (NAAAP) which is the largest and fastest growing 501(c)(3) inclusive organization. He holds a Bachelor of Science (B.S.), Business Administration in Marketing from Montclair State University and now studying at Louisiana State University for an MBA. He is bilingual in English and Korean.

Abstract:
In our industry, it is widely known the slow moving companies give their nimbler competition an advantage to dominate the marker even if their product is not superior. Fast movers are flexible and adaptive to rapidly changing dynamic business environment. Those that can capitalize on opportunities and better navigate risks and challenges with quicker adaptability will triumph from competition.

At Aton (A Henlius Company), we have established SMART STRATEGIES that enabled acceleration of pipelines to market through experience including 500 commercial batch productions, 100+ Tox & clinical batches, 30+ molecules, 50+ IND approved, and 100% tech transfer success rate. What we have learned from all our experience, is PLATFORM APPROACH that enable us to successfully accelerate molecules to market. Our platform strategy allows us to shorten timeline efficiently by integrating all aspects of production of drug substance and drug product. In this presentation, Aton will share how to deploy smart platform approach strategies to accelerate molecule to market.

Linda Zhou
Partner

Jian Jiang
Partner

K&L GATES

A New Era for Biotech Founders

Linda Zhou focuses her practice on the representation of start-up, emerging growth, and public companies, with a special emphasis on corporate and securities law, private and public financings, mergers and acquisitions, and corporate partnering transactions. Her practice also encompasses forming and representing venture capital and private equity funds.

Linda represents a wide variety of technology companies, ranging from consumer internet, software, and telecommunications to life sciences industries, as well as a number of leading venture capital firms. Linda has extensive experience with cross-border transactions. She has developed a robust practice guiding clients in their cross-border investments and global acquisitions and operations.

Jian Jiang is a PTO-registered patent lawyer with a Ph.D. from the University of North Carolina at Chapel Hill in Materials Science. Jian's experience includes drafting and prosecuting U.S. patent applications involving Electrical Engineering, Computer Software, Mechanical Engineering, Chemistry, Chemical Engineering, Materials Science, and Biotechnology and in the food, consumer electronics, telecommunication, and medical device industries. She has prosecuted international patent applications in Japan, Korea, China, Europe, and other regions all over the world and has counseled clients on international IP strategies. Jian also conducts IP due diligence and prepares IP and technology licensing agreements.

Prior to law school, she received in 2007 her Ph.D. in Materials Science from the University of North Carolina at Chapel Hill where she researched detection and quantification of signature peptides from biomarkers for infectious diseases or cancers using MALDI (MS and MS/MS), developed and optimized for diagnosis of human diseases a peptide chip method, researched detection and quantification of EGFR in human tumors, researched detection and quantification of francisella tularensis in mice samples, tested and optimized immunoaffinity columns, researched cancer pathology in human cells using quantitative PCR, researched synthesis of a new polymeric drug delivery system and its application in siRNA delivery for gene therapy, etc.

Before she came to the United States to pursue her Ph.D., she received in 2002 her B.S. in Polymer Materials & Engineering from Fudan University in Shanghai, China. She is fluent in Mandarin, Shanghainese, and Cantonese.

Abstract:
The recent BioPharma trend and the current regulatory environment presents the biotech founders some unprecedented challenges and opportunities. We are going to take the audience for a cruise to review and discuss these challenges and opportunities in such an interesting time.

YangZhou Wang, PhD
Chief Executive Officer

PORTON ADVANCED

Leveraging innovative processes and manufacturing to accelerate the quality development of advanced cell and gene therapeutics

Dr. YangZhou Wang currently serves as the Chief Executive Officer for Porton Advanced Solutions. In his current role, Dr. Wang is responsible for the global business expansion and development of Porton Advanced.

Dr. Wang has more than 20 years of managerial, operational and commercial experience in the biotech and life science industry. He is an accomplished international business leader growing multi-national corporations. Prior to joining Porton Advanced, he served as the Chief Executive Officer at Analytical Biosciences, a single cell genomics startup with operations in both China and the U.S. He also served as the Chief Operation Officer at Crown Bioscience, where he oversaw global operations and business performance at Crown's operation sites in China, U.S.A., and Europe.

Dr. Wang also served as a Vice President of international business development at WuXi AppTec, where he was responsible for the global business expansion in its pre-clinical and clinical testing services. He also worked at Life Technologies/Applied Biosystems where he was a leader in corporate development for strategic NGS-based research and diagnostic alliances. While at Life Tech, he also served as an M&A Integration leader for a bioinformatics company that Life Tech acquired in the U.S. and oversaw its integration into the parent company. Dr. Wang also held academic appointments and managerial roles in universities and industrial research labs.

Dr. Wang received his PhD in Cellular Molecular Biology from Roswell Park Cancer Institute, State University of New York at Buffalo. He also holds a Master of Engineering in Computer Science from the University of Colorado at Boulder.

Abstract:
The field of gene and cell therapy (GCT) has experienced remarkable growth recently, due to its promises of extraordinary clinical benefits to patients. Many mechanisms of action are being intensely investigated for efficacy, safety and scalability. Due to the complexity of biology and the personalized nature of GCT, critical barriers to approval are often not clinical efficacy but manufacturing/CMC quality. A reliable CDMO must possess both manufacturing capabilities and sufficient capacity. Furthermore, it must innovate in process development (PD) and analytical development (AD) to support the complicated and customized needs of CMC for sponsors in their IND and clinical studies. FDA mandates rigorous control of the manufacturing process and appropriate in-process and lot release testing, all crucial to ensure the safety, quality, and lot-to-lot consistency of GCT. Porton Advanced Solutions works with sponsors in all of the above areas with the goal to accelerate GCT development for the benefit of patients. In this talk, we discuss the market trend, the critical importance of CDMO to sponsors, and innovation in GCT PD/AD and CMC.

Tracy Zhao (Menglin Zhao)
Senior Field Application Scientist

BIOSYSTEMS Acro

Selection of Raw Materials for Cell & Gene Therapy

Tracy Zhao is the West Coast Field Application Scientist at ACROBiosystems. She worked as a staff scientist in PerkinElmer for 3+ years, with rich experience on development of IVD Immunoassay diagnostic kits. At ACROBiosystems, Tracy is working with leaders in both industry and academia to support their research needs. Tracy is part of a team that helps to guide in the use and development of recombinant proteins that can be used for COVID-19, CAR T-cell therapy, as well as many other immune and auto-immune conditions. As a member of ACRO, she is highly interested in leveraging the company's resources and state-of-the-art technology to help our partners and clients develop next-generation therapies.

Abstract:
The success of cell and gene therapy (CGT) products, is significantly dependent upon the process and material-selection strategies set in the early stages of development. When choosing raw materials for use in CGT manufacturing, four key raw material characteristics need to be followed: They are Material identity, purity, lot to lot consistency, storage and stability respectively. Material identification, used to determine any risk that the material may present to the facility, operator and the final cell therapy product. Performance testing of the raw material used to reflect the intended use of the product as the raw material. Normally, Research-use only (RUO) materials are commonly used for early-stage research. For long-term material procurement strategy, best option is materials developed under the appropriate GMP requirements. However, implementing GMP products in the early preclinical or stages may not be feasible due to higher cost. So. Identifying key material grade transition points is critical in developing a cell therapy product. Since these ancillary materials have a significant impact on both the quality and safety of the final products.

Xiaoxi Wei, PhD
Co-founder & CEO
X-THERMA

Next-Generation DMSO- & Serum-Free Cryopreservation for Cell Therapy Manufacturing and Processing

Xiaoxi Wei, PhD, is a co-founder and CEO of X-Therma Inc, award-winning entrepreneur and chemistry professional in the area of supramolecular assembly and biomimetic nanoscience. Dr. Wei is the inventor of X-Therma's core technology based on hyper-effective ice prevention materials. She is also the lead author of eight peer-reviewed research papers and has been awarded 6 patents. Dr. Wei has served as Healthcare Advisor - UC Regents Working Group on Innovation Transfer and Entrepreneurship, as Vice Chair of the Younger Chemists Committee of the American Chemical Society, and as Scientific Advisor to the Life Extension Foundation. She graduated with honors from Ningbo University in 2007, where she studied biotechnology. In 2014, she received her Ph.D. in medicinal chemistry from SUNY-Buffalo and has since served as Principal Investigator for $5.4M in government R&D grants leading X-Therma's development.

Abstract:
The regenerative medicine field is rapidly advancing, with many pivotal trials underway. As the field moves into large-scale commercial manufacturing, cryopreservation becomes an ever more critical component for ensuring maximum efficacy and long shelf-life during end-to-end production. However, the potency and yield of fragile cell types, such as induced pluripotent stem cells and genetically modified cell-based immunotherapies, are significantly reduced post-cryopreservation due to ice damage and genomic and in vivo toxicity associated with current cryoprotectants (e.g. DMSO). These issues further limit the realization of off-the-shelf advanced regenerative medicine products, such as those being developed in allogeneic cell therapy and tissue engineering.

X-Therma applies convergent biomimetic nanoscience to solve this unmet need in cryopreservation, pioneering a novel chemistry that is inspired by natural antifreeze protein, and developed with modern drug discovery methods. The fully synthetic molecules are non-toxic, chemically stable, and exhibit surprising dual ice control function, superior to antifreeze proteins and 500x more effective than non-colligative small molecule cryoprotectants. The resulting product XT-Thrive is a DMSO-, serum-, and protein-free and completely chemically-defined cryopreservation solution.

Third-party validations have demonstrated superior post-thaw cryopreservation outcomes for both cell viability and functionality with a variety of engineered cell lines and therapeutic cell-based products. XT-

Thrive is extremely process-friendly and can be directly plugged into current workflows without requiring any specialized instrumentation, replacing the leading DMSO-based cryopreservation solutions. Empowered by negligible toxicity, XT-Thrive removes bottlenecks for large batch production and enables a highway of premium quality cell products for the many patients in need.

Ilean Chai
Associate Director of Business Development
BIORTUS

Biortus, from gene to lead: your partner in drug discovery

Ilean Chai, associate Director of Business Development for Biortus. Graduate training at UCSD in Structural and Chemical Biology. Prior industry experience at Gilead Sciences in Foster City and Calico in South San Francisco.

Abstract:
Biortus is a one-stop shop for gene-to-lead generation with modular services in protein production, assay development, fragment screening and structure determination by X-ray Crystallography and CryoEM. Founded in 2009 by scientists for scientists, Biortus has partnered with numerous research institutions, biotechnology companies and pharmaceutical companies at various stages and sizes. Our newest site in Boston is now available for 2-way sample shipment and serves as the headquarters for our off-the-shelf Protein Catalogue.

Today, we will be showing a few examples of our gene to lead generation pipeline in the context of fragment screening and SAR, the result of having mature membrane protein production teams and CryoEM experts under one roof as well as our recent publication of a gene to lead project in Nature Communications. Come learn about how we can support your drug discovery needs.



Deyong Wen
Executive Director, Chief Executive Officer (CEO) of Fosun Pharma

Mr. Wen is currently the Executive Director, Chief Executive Officer of the Fosun Pharma and holds directorships and management positions in certain subsidiaries of the Company. He joined the Group in May 2002 and served as the vice president of the Company from June 2016 to October 2020, the senior vice president of the Company from October 2020 to January 2022, the co-president of the Company from January 2022 to April 2022, the President of the Company from April 2022 to June 2022, has served as the Chief Executive Officer of Fosun Pharma since June 2022 and was appointed as an Executive Director of the Company on August 2022. Mr. Wen is currently a non-executive director of Sinopharm Group Co. Ltd. (stock code: 01099), a director of China National Medicines Corporation Ltd. (stock code: 600511), and the chairman of the supervisory committee of China National Accord Medicines Corporation Ltd. (stock code:000028).

Yuanyuan Qi
Chief Operating Officer of Fosun Kite Biotechnology Co., LTD

Mr. Qi is the Chief Operating Officer of Fosun Kite Biotechnology Co., LTD., responsible for the company's external cooperation and the commercial development of the first CAR-T (chimeric antigen receptor T-cell immunotherapy) in China, including BD, supply chain, procurement, and access. Previously, Mr. Qi was a director in the strategy department of Fosun Pharma and participated in various major investment and cooperation projects within the Group, including the establishment of the joint venture of Fosun Kite and Fosun Lead. From 2008 to 2015, he was engaged in tumor immunity and autoimmune disease research at Shanghai Immunology Research Institute, Shanghai Jiao Tong University.

Moderator

Wei Wu, PhD
Principal of Johnson & Johnson Innovation- JJDC

Wei is a Principal of Johnson & Johnson Innovation- JJDC, the corporate venture group of J&J. She initiates and manages equity investments in biopharma, medical device, and consumer health, to drive innovation and fuel new and sustainable businesses. Prior to joining JJDC, Wei was a Senior Associate at Illumina Ventures with a focus on genomics-enabled precision medicine including therapeutics, diagnostics, and life science tools. Prior to that, she was the Director of Healthcare Investment and Business Development of BOE Ventures where she focused on VC fund investment, direct investment, and business development opportunities at the intersection of technology and life sciences. Before becoming an investor, Wei was a R&D project lead at NuGEN Technologies (later acquired to become TECAN Genomics). Wei received her PhD from UCLA in Biological Chemistry and completed her postdoctoral research in the Department of Pathology at Stanford University. She received a Bachelor of Science in Biological Sciences from Peking University, China.

Guoliang Yu, PhD
Co-Founder, Executive Director, Chairman and Chief Executive Officer of Apollomics

Dr. Guo Liang Yu is a co-founder, Executive Director, Chairman and Chief Executive Officer of Apollomics. Dr. Yu has been one of the key management members of the Company and has been actively involved in its business, strategy and operational management since its establishment. He has over 31 years of experience in the pharmaceutical industry and academic research. He is a serial entrepreneur and has co-founded over ten startup companies in biotech and the healthcare sectors, including Immune-Onc Therapeutics, Inc. in Palo Alto, United States. During his co-founding of our Group, Dr. Yu was the executive chairman of Crown Bioscience International and he was also a venture partner with OrbiMed Asia Limited.

Dr. Yu obtained his Ph.D. degree in molecular biology from the University of California, Berkeley in the U.S. He has served important roles in numerous social organizations, including the founding president of the Chinese Biopharmaceutical Association USA. Inc. and as a board member of Ray Wu Memorial Fund. Dr. Yu is currently a member of the Board of Directors of the following companies: Jiangsu Qyuns Therapeutics Co., Ltd., Immune-Onc Therapeutics, Inc., Zhejiang Innoforce Pharmaceuticals Co., and Inmagene Biopharmaceuticals.

Dajun Yang, PhD
Chairman, Executive Director and Chief Executive Officer of Ascentage Pharma Group

Dr. Dajun Yang, is the Co-Founder, Chairman of the Board, and CEO of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma currently has eight potential First-in-Class or Best-in-Class innovative drug candidates in Phase I/II clinical developments in China, the U.S. and Australia. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-Tech R&D Program (the 863 Program) and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 Dushu Lake Prize for the Most Influential Leader in Drug R&D. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor at Sun Yat-sen University Cancer Center, Vice Director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association.

Patrick Y. Lu, PhD
Chairman, Executive Director, President and Chief Executive Office of Sirnaomics

Dr. Patrick Y. Lu founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage. Dr. Lu brings 25+ years of nucleic acid drug development experience at Novartis, Digene, and Intradigm, where he was a co-founder. He has helped Sirnaomics raising over $270 million and develop the novel siRNA therapeutic, STP705, for the treatment of cancer and fibrosis diseases.

Dr. Lu has published more than 50 articles and book chapters and holds 35 issued and pending patents. Dr. Lu received his PhD from Sun Yat-sen University, China and completed his postdoctoral work at the University of Maryland at College Park and Georgetown University in 1992. He has been an invited speaker in many international conferences throughout the world. Dr. Lu has been awarded a number of grants from NIH, the State and County governments.

Jason Zhu
President of Henlius

Mr. Jason Zhu, President of Henlius, is responsible for the company's global product development and management of certain functional departments. Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. Jason holds a bachelor's degree in clinical medicine form Shanghai Medical College of Fudan University and an EMBA degree from CKGSB.

Moderator

Alex J. Zhang, PhD, MBA
Managing Director of Lifespan BioLabs

Dr. Zhang is Managing Director of Lifespan BioLabs, a life science accelerator and investor based in San Francisco Bay Area. He was the CSO of Hanhai Holdings Group, and the CEO of Hanhai Silicon Valley, Inc. Prior to Hanhai, Alex was the Co-founder and Managing Partner of Enverest, LLC. Prior to founding Enverest, Dr. Zhang spent over four years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding $10 M, and played a key role in several billion dollar acquisitions in IVD and MedTech areas. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. Over the past decade, Dr. Zhang has been advising a number of successful biotech, MedTech and digital health startups and VC firms based in Silicon Valley.

Dr. Zhang is a Board Member of CABS and has served a number of leadership roles, including being the President in 2017-18. Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. His research has led to publication of 17 peer reviewed articles and 4 patents.

Wenyan David Shen, PhD
Founder and CEO of Proteologix Inc.

Dr. Shen is a leading expert with more than 20 years of experience in the antibody and therapeutic protein field, and has a proven record of advancing pipelines from discovery to proof-of-concept in clinical stage to registration. Before founding Proteologix, Dr. Shen held leadership roles in biopharma companies including Senior Vice President, Biologics and CMC at NGM Biopharmaceuticals and Vice President, Global Head of Biologics Development at TEVA Pharmaceuticals. Prior to TEVA, Dr. Shen was Executive Director, Biologics Research and GlycoFi at Merck where he oversaw overall biologics pipeline from discovery to preclinical development. His professional career started at Amgen where he held positions of increasing responsibility, including site-head for the Protein Sciences Department in San Francisco, and was critical in advancing more than eight antibody drug candidates from research to clinical development and regulatory approval, including evolucumab (anti-PCSK9), romosozumab (anti-sclerostin) and denosumab (anti-RANKL). In addition, he has developed the mammalian full IgG display technology that is now widely used by the antibody field. Dr. Shen graduated from East China University of Science and Technology and received a PhD from University of Toronto. He completed post-doctoral training at the Whitehead Institute for Biomedical Research.

George Wu, PhD
Co-Founder and Chief Executive Officer, Amberstone Biosciences Inc

George Wu is a life sciences technology innovator with great passion in developing innovative cross-field technologies to address unmet market needs. He is the Co-founder and CEO of Amberstone Biosciences, a California based biotech with a focus on developing a next generation of tumor microenvironment activated immunotherapeutics. He has published dozens of manuscripts in cancer biology, immunology, high-throughput drug discovery, single cell technologies, medicinal chemistry, and molecular diagnostics. With numerous patents relevant to anti-tumor molecules or single cell technologies, Wu is a recognized inventor committed to making a difference for patient healthcare. Before founding Amberstone, he was President and COO of GeneTex International, where he was closely involved in antibody and research product development, business scaling, and cross-border merger and acquisition. He received a BS in biology from the University of Science & Technology of China, and a PhD in molecular medicine from the University of Texas Health Science Center, San Antonio. As a Susan Komen Research Fellow at the University of California, Irvine, his primary focus was small molecule anti-tumor drug discovery and translational research.

Xiaoyu (Janice) Zang, PhD
Co-founder and Chief Executive Office, N1 Life

Dr. Xiaoyu (Janice) Zang is the co-founder and CEO of N1 Life, a Silicon Valley based biotech startup company spun out of Stanford University. The company is translating innovative drug delivery technologies evolved from Stanford to accelerate the process, improve the success rate and cut the cost for drug development. N1 Life has raised over 10 million USD of funding so far and has established R&D collaboration with Stanford University, as well as pharma and biotech companies to coordinate global innovation resources and accelerate technology translation. At present, the company's pipeline products and delivery technologies focus on oncology, dermatology, and ophthalmology.

Dr. Zang received her PhD in Chemistry at Stanford University, where she developed expertise in synthetic chemistry, nanotechnology, and drug delivery; published in top-tier peer-reviewed scientific journals, including PNAS, JACS, ACS NANO, ACS Chemical Biology; inventor of 2 Stanford patents.

Dandan Dong, PhD
Chief Business Officer of ArriVent Biopharma

Dr. Dandan Dong is the Chief Business Officer of ArriVent Biopharma. Dr. Dong has more than 15 years' experience in global healthcare investment. Before joining ArriVent, Dr. Dong was the Managing Director of Vivo Capital, and the General Partner of Vivo Capital Innovation Fund II & PANDA Fund. Over her career she has led multiple successful investments in innovative drugs in both the U.S. and Greater China Market. She has been focusing on cross border opportunities, incubated multiple biotech companies with cross border theses. Most recently, she was the Chief Business Officer, Executive Board member of Visen Pharmaceutical, a joint venture between Ascendis Pharma (NASDAQ: ASND). As a founding member, she led the effort of in-licensing core pipelines, designing corporate strategy, recruiting key management, financing and was the chair of Joint Collaboration Committee. She also co-founded RareStone Group, to build the first rare disease ecosystem in the Greater China, served on the board, the transaction committee and financing committee.

Announcing 2022 CABS

K. Fong Award in Life Sciences

*The CABS K. Fong Award Committee is very pleased to announce that **Dr. SCOTT LIU** is the winner of the 2022 CABS K. Fong Award in Life Sciences for his outstanding contribution to the development of multiple biologic products from research to launch.*

Dr. Scott Liu is the Founder, Chairman, and CEO of HanchorBio Inc., a global biotechnology company pioneering the development of next-generation immunotherapies. As a life-science entrepreneur and successful biotech company-builder, Dr. Liu was one of the global partners of Fosun International Limited and Co-founder, President, and CEO of Shanghai Henlius Biotech Inc. As a commercial-stage global biopharmaceutical company with the focus on high-quality, affordable, and innovative biologic medicines, Henlius is listed on Hong Kong Stock Exchange (2696.HK) with a market value of over US$ 1.1 Billion. During his tenure with Henlius, Dr. Liu led the product development initiatives of over 30 biosimilars, novel monoclonal antibodies, and bispecific antibodies, and successfully launched 5 commercial monoclonal antibody products in China and Europe.

Scott Liu, PhD

Dr. Liu has over 30 years of experience in managing corporate development, strategic portfolio, equity, cGMP quality operation, and CMC regulatory affairs. He has been instrumental in the development of the Technical Guidelines for the Research, Development and Evaluation of Biosimilars to promote globalization of the biopharmaceutical industry in China. Additionally, he has participated in development of multiple biological medicines, including Orencia® (for rheumatoid arthritis), Vectibix® (for colorectal cancer), Hanlikang® (rituximab biosimilar), Hanquyou®/ Zercepac® (trastuzumab biosimilar), Handayuan® (adalimumab biosimilar), Hanbeitai® (bevacizumab biosimilar) and Hansizhuang® (serplulimab, novel anti-PD1).

Prior to founding HanchorBio and Henlius, Dr. Liu had previously served several executive positions such as Vice President of Scientific Affairs at United Biomedical Inc., the Founding Director of the Biologics Quality Control Department at Bristol-Myers Squibb (Syracuse, USA), and the Director of Quality Analytical Laboratories at Amgen (Fremont, USA). Dr. Liu has authored or co-authored multiple scientific papers and has been an invited speaker in conferences with topics ranging from Biologics Process Development, Biomanufacturing, Oncology Biologics and Immuno-Oncology. He received his Ph.D. in biology at Purdue University and completed his post-doctoral training at Stanford University.

About the CABS K. Fong Award in Life Sciences

CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates must be nominated by an active member of CABS. Selection criteria are based on candidate's accomplishments in life sciences and contribution to the life science community, including one or all of the following:

- *Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or research reagent/equipment markets.*
- *Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.*
- *Significant contribution to the CABS community and promotion of international collaborations in life sciences.*

About Kenneth Fong, PhD

Kenneth Fong, PhD. has spent the last 32 years in the biotech industry after completing his academic pursuit in biomedical research.

He is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was sold to Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated more than 10 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 10 companies that are worth more than $3 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2006, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

Ken obtained his PhD from Indiana University and his BS from San Francisco State University.

Past recipients of CABS K. Fong Awards

***2021 Dr. John O. Link,** Vice President of Gilead Sciences and **Dr. Xian-Ping Lu,** Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD, for their extraordinary achievements in research, entrepreneurship, and innovation.*

***2019: John V. Oyler, PhD.** Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.*

***2018: Yuling Luo, PhD.** Founder, CEO and Chairman of Alamar Biosciences, and **Dr. Guoliang Yu**, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.*

***2017: Yinxiang Wang, PhD.** Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China, and **Dr. Edgar Engleman,** for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.*

***2016: Gerald Chan, PhD.** co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.*

***2015: Irving Weissman**, PhD. of Stanford University, for his pioneering work in stem cell research.*

***2014: Ge Li, PhD.** Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China and **Dr. Hing L. Sham**, formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and lopinavir.*

***2013: Peter Hirth, PhD.** Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market and **Dr. Jean Cui,** formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.*

2021-2022 Selected CABS Activities



2021 BioPacific Conference

The 2021 BioPacific Conference, also the 22nd Chinese American BioPharmaceutical Society (CABS) Annual Conference, was successfully held on October 30, 2021 virtually. The theme of this year's conference was "Passion for Better Medicine, Leading Biotechnology and Innovation."

The conference included two keynote talks, two K. Fong award speeches, six scientific speeches, 10 breakout room presentations, and two panel discussions by industry and academic leaders. The topics covered scientific R&D, business trends, and regulatory considerations. Experts from the forefront of life science innovation shared and discussed the current status and future prospects of cancer therapeutics, new strategies in drug development, precision medicine for individual patient treatment, and strategies for regulatory approvals. Other hot topics included clinical studies in the US and China; cross-border development; IPO considerations and strategies; and investment opportunities.

Dr. Carrie Wang, the president-elect of CABS and chair of the organizing committee of the 2021 BioPacific Conference, gave welcome remarks to kick off the conference. Dr. Yang Tian, the president of CABS, emphasized how CABS has grown over 400%, reaching over 30 countries in the past two years. He highlighted that CABS had hosted many virtual events that had rendered CABS global reach in the past years.

In the first keynote speech, Dr. Randy Schekman, a 2013 Nobel laureate and professor at UC Berkeley, presented his latest research about the transfer machinery of Cas9/gRNA through cell-cell contact. In the second keynote speech given by Dr. Greg Verdine, professor at Harvard, discussed recent advances in the discovery of Helicon peptides and how this new modality can enable the druggablity of the majority of human proteins.

Dr. Ken Fong presented the 2021 CABS K. Fong Award to John O. Link, PhD, former VP, Gilead Sciences, Inc., and Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences. Dr. Lu shared his experience of becoming a trailblazer in changing the pharmaceutical landscape of China from a manufacturing focus to discovery and development. Dr. Link shared the failures, successes, learnings and course alterations over his 15-year journey in the discovery and development of Lenacapavir, a twice-yearly dosed first-in-class HIV capsid inhibitor with patient-focused treatment to end the epidemic of HIV.

The six scientific speeches covered a wide range of exciting topics. Dr. Gary Starling, CSO of Xyphos BioSciences, reviewed available immune therapies and the challenges in the field. Dr. Joseph Wu, professor at Stanford, discussed the usage of iPSC-derived cardiomyocytes for drug discovery and precise medicine for rare inherited cardiovascular diseases. Dr. Matt Repasky, senior vice president at Schrödinger Inc., discussed three practical vignettes of applying machine learning to active drug discovery programs. Dr. Arthur Reingold, professor at UC Berkeley, presented the status of the COVID-19 pandemic and efforts to minimize its impacts. Dr, Sharon Liang, vice president at Burning Rock Dx, shared her view on FDA's regulatory considerations for cancer early detection tests and companion diagnostics. Dr. Carrie Ling, assistant director at Hong Kong Science and Technology Parks Corporation, presented their new innovation platform with focuses on healthcare, artificial intelligence and robotics technologies.

The first of the two panel discussions was led by Dr. Janet Xiao, a patent partner at Morrison & Foerster LLP. Three panelists, Dr. Neil Desai, founder and CEO at Aadi Bioscience, Dr. Sean Cao, managing director at CBC Group, and Mr. Chuck Comey, partner at Morrison & Foerster LLP, discussed various considerations in IP strategies and investment decisions in life sciences. The second panel discussion was led by Dr. Cheni Kwok, managing partner and founder of Linear Dreams. Four panelists, Edward Harringon, CFO at Genentech, Inc., Dr. Guo-Liang Yu, CEO at Appollomics, Dr. Dewen Zeng, Head of Search and Evaluation at BeiGene, Inc., and Cariad Chester, a partner at TGG Crossover, shared their insights in how to strategically build partnerships and make investment decisions in the biotech industry and discussed future trends of biotech in the global market.

In the noon breakroom sessions, ten different presentations with various topics were provided to attendees. The topics include new development of technologies and tools that aid research in cell and gene therapy, regulatory process in the US, future of targeted therapies in cancer, as well as clinical trials in China.



2022 Career Advisory Network (CAN) Program

One of the CABS missions is to promote professional growth of its members through mentoring and networking. To fulfill the mission, Business and Career Development Committee of CABS relaunched a 6-month online Career Advisory Network (CAN) program with a Mentor-Mentee Career Roundtable and a large group networking session on March 28, 2022. There are 26 mentees in this year's program and they are partnered to 19 mentors. CAN aims to cultivate members to be the next generation of healthcare/life sciences professionals and leaders through mentoring, skill building, and networking. Mentors and mentees were expected to meet once monthly during the months of May through October 2022 (in person or virtually). Graduation will be in the early of December.

2022 Tax Season Seminar

CABS invited Mr. Bin Zhai, CPA, FP, MBA and Partner from Zhai & Wang, LLP, to host a tax virtual seminar on June 11, 2022. This seminar covered all necessary information including updated tax rate and tax bracket, pandemic stimulus related benefits, tax deduction and credit, investment capital gain tax, CA tax, qualified business income, foreign financial income, investment option and selling strategies, and tax planning strategy under the current law. This seminar helped attendees to learn how to quickly and correctly finish their tax return in 2022 and successfully plan their tax return in 2023.



Executive Presence - Build Your Professional Image

Building one's professional image is important for one's career success, but is often overlooked. To enable improvement to this end for its members, CABS co-hosted one onsite free event titled "Build Your Professional Image" with Silicon Valley Women Federation, and Alliance Global Green Development on 25th June, 2022. Ms. Lilly Cook from Association of Image Consultants International spoke on building confidence from one's image, language, and poise. Ms. Cook shared her knowledge, vision, and tailored combination of fabrics, styles, colors for many attendees.

BioPacific Toastmasters Club Open House

The CABS-sponsored BioPacific Toastmaster Club successfully hosted an in-person open house at San Mateo Central Park on August 20th, 2022. This event was special in two ways: it was a kick-off party to resume on-site meetings after two years of being online, and to celebrate the club's 5th anniversary. There were 15 attendees at this event. All enjoyed the wonderful speeches while improving their public speaking skills with the blue sky and fresh air. The BioPacific Toastmaster Club now hosts a hybrid meeting every Saturday morning.

Antibody-Based Drug Development from R&D to Commercialization

One of the major missions of the Science & Technology Committee (STC) of CABS is to keep CABS members abreast with the latest development of the related fields through educational seminars. On August 27th, 2022, STC held a workshop on antibody-based drug development in a hybrid format (both in person and online). It covered the topics of chemistry, manufacturing and controls (CMC) and the development process from Investigational New Drug (IND) to Biologics License Application. This event was sponsored by Aton Biotech, and more than sixty people attended this event.

Five industry experts led the discussions.

Ms. Wei Huang, COO & SVP of Shanghai Henlius Biotech Inc., gave an overview and details of CMC and discussed manufacturing strategies of either building one's own CMC or outsourcing. As an ex-FDA CMC team lead, Dr. Sandy Yan, Executive Director of Regulatory Affairs of Shanghai Henlius Biotech Inc., spoke about CMC considerations from FDA's perspective and provided examples of potential holding issues of CMC review for an IND. Midway through the workshop, Dr. Lifeng He, VP of Global BD & Marketing of Aton Biotech, introduced their experience and track record on antibody-based drug manufacturing. Dr. M. Tim Tian, an independent consultant for biologics CMC, discussed procedures and CMC execution in CDMOs. Rounding out the workshop, Dr. Fan Chen, SVP of TrueBinding, shared their successful story in completing the entire process of developing an antibody drug product in 12 months.

This event is the first time STC has had a scientific seminar on an in-depth discussion of CMC and CDMO of antibody-based drugs. In addition to the early drug discovery workshops, STC will continue to showcase additional late-stage drug manufacturing and development workshops and seminars.

Taking the Pulse of Life Sciences Innovation in a Changing World

The world is becoming more complex, fraught with increasing possibilities for conflict over economic competition and geopolitical tensions. One of the major missions of the International Collaboration Committee (ICC) of CABS is to help CABS members to be aware of challenges and discover opportunities in international collaboration, partnership, business development and investment.

On October 28th 2022, ICC held a 3.5-hour BioPacific Pre-Conference Symposium in a hybrid format (both in person and online) with over 200 attendees. It covered many important topics related to international collaboration, especially between the US and Asia. The event was sponsored by Wuxi Biortus and held at Morrison Foerster Palo Alto Office.

The keynote speech by Helen Chen, the Managing Partner of L.E.K Consulting, gave an overview of the Chinese pharmaceutical landscape, analyzed its market and policy trends, and discussed potential opportunities for Western biopharmas in this changing world.

In addition to Helen, five global business experts (Chuan Sun, Partner of Morrison Foerster; Cheni Kwok, Managing Partner & Founder of Linear Dreams; Ji Li, Entrepreneur-in-Residence of Lilly Asia Ventures; Anthony Hsiao, Principal of ZhongMei Consulting; and Shutian Liu, Co-founder of Button) from the Bay Area, Singapore, Hongkong, and Shanghai joined the panel session and shared personal insights on many hot topics, including:

- US-China partnership trends for innovative medicine;
- Funding innovations in life sciences;
- Key learnings from US-China cross-border transactions;
- US-China product development strategy;
- The impact of rising geopolitical tension on life science companies across the Pacific;
- Valuation of new medicines.

This event is the first in-person event that ICC has held since the onset of COVID-19 pandemic. ICC will continue to invite world-class experts to discuss the latest international collaboration challenges and opportunities for our members.

We are a purpose-driven company imagining a world without cancer.

At Apollomics, we let science drive our decision-making to advance our programs.We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.

Anti-Cancer Enhancers

Immuno-Oncology Drugs

Tumor Inhibitors



- We are committed to the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.
- Our science-driven approach powers a pipeline of next-generation, combination, and pan-cancer therapies for patients globally.
- Dual Presence in the U.S. and China and Executing a "Dual" In-licensing Strategy.

We are an ideal partner for companies from the West interested in entering the China market, as well as companies from China interested in accessing international markets.We have established numerous strategic collaborations to increase our pipeline of assets, explore new treatment areas, and expand our global reach.

apollomics 冠科美博

apollomicsinc.com

InnoHK Research Cluster

28 No. of Research Laboratories

2000 No. of Researchers

12 No. of Economies (including Hong Kong)

30+ No. of World-renowned Institutions

16 health-related research centres in collaboration with world-renowned institutions including Stanford University, University of Oxford, University of Cambridge, Imperial College London and ETH Zürich in 6 main areas below:

THERAPEUTICS

BIOINFORMATICS

VACCINES

DIAGNOSTICS

MEDICAL DEVICES

TRADITIONAL CHINESE MEDICINE

InnoHK.gov.hk

FOSUN PHARMA™ USA INC.

www.FosunPharmaUSA.com

We are a US-focused innovative specialty pharma company driven by our internal R&D and strategic partnerships.



Seeking strategic partnerships across many therapeutic areas and modalities.

THERAPEUTIC AREAS

- Oncology
- Autoimmune/Inflammation
- Metabolic Disease
- Neuroscience
- Rare Diseases

DRUG MODALITIES

- Small Molecules
- Antibodies, including monoclonal, bispecific and ADC
- Gene Therapy/CAR T cell therapy
- Stem cell therapy
- Others (Oligos, peptides, etc.)

Learn more about our Opportunities & Careers

SCAN HERE

INNOVATION FOR GOOD HEALTH

Fosun Pharma USA Inc.
104 Carnegie Center, Suite 204
Princeton, NJ 08540
(609) 250-2802

Fosun Pharma USA Inc., is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK).

FOSUN PHARMA 复星医药

Global Commercialization System

·＞**6,900** Staffs in the Commercialization Team
·＞**40** Countries/Regions
·＞**1,400** Staffs in the Overseas Commercialization Teams in Africa, Europe and the United states

Global Manufacturing System

Pharmaceutical Manufacturing

Over 10 production line for API and formulation of Yao Pharma, Wanbang Biopharmaceuticals and Guilin Pharma received GMP certification for the U.S., Europe and other markets.

Medical Devices

Fosun Med-tech integrated several subsidiaries at home and abroad, initially formed 3 major business divisions with medical aesthetics, respiratory health and professional medical care.

Medical Diagnosis

6 R&D & Manufacturing base, 700+ NMPA Medical Device Certificate, 100+ CE, FDA and other overseas certification

Seeking approved or late-stage innovative drugs

to treat oncology, immunomodulation, metabolism and digestive system, as well as central nervous system diseases.

Key Innovation Products

Artesum®
(Artesunate for injection)

Han Li Kang
(Rituximab injection)

Han Qu You
(Trastuzumab injection)

Han Si Zhuang
(Serplulimab injection)

Jie Bei An
(Azulfidine Tablets)

COMIRNATY®
(mRNA COVID-19 vaccine)

Akynzeo
(Netupitant and Palonosetron Hydrochloride Capsules)

Su Ke Xin
(Avatrombopag Maleate Tablets)

Otezla
(Apremilast tablets)



Yi Kai Da
(Axicabtagene Ciloleucel Injection)

Open R&D Ecology

Core Therapeutic Areas



· In 2021, the annual R&D expenditure was RMB **4,975** million, representing an increase of **24.28%** YOY

· In the first half of 2022, R&D expenditure was RMB **2,399** million, representing an increase of **22.77%** YOY

· As of 30 June 2022, more than **260** pipeline projects, including innovative drugs, biosimilars, generic drugs and consistency evaluation items are under research.

Innovation for Good Health

Our official Website:
www.fosunpharma.com

Scan the QR code to follow our Wechat Official Account

Contact:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Building A,No.1289 Yishan Road,Shanghai,
200233,P.R China
Tel: +86-21-33987000
Fax: +86-21-33987020
Website: www.fosunpharma.com
E-mail: chenhong1@fosunpharma.com

ACRO BIOSYSTEMS | *Where Proteins and Innovation Advance Biomedicine*

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world' s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as **A**CROBiosystems, **b**ioSeedin, **C**ondense Capital, and ACRO**D**iagnostics.

> 6,000 Customers

> 70 Countries

> 100,000 Scientists

Our Clients

Pharma | Biotech | Diagnostics | Vaccine | CRO | Academia

Products and Services

ACROBiosystems' brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.



ACROBiosystems +1 800-810-0816(US / Canada) +86 400-682-2521(Asia & Pacific) techsupport@acrobiosystems.com 1 Innovation Way, Newark, DE 19711

HanchorBio

navigating new territory in immuno-medicine

team

over several decades of cumulative industry experiences with **track-record of success** in global drug development

strength

deep knowledge in protein structural modeling, design, and engineering; state-of-the-art animal facility with **>90 tumor animal models**

science

unique science-driven approach of engaging with **both innate** (cytokines) **and adaptive** (T-cells and B-cells) **immunity**

technology

FBDB™ platform **overcomes** the resistance of current **anti-PD1/L1 therapies**; **8+ candidates** demonstrate **superior** tumor cell killing and growth inhibition

Fc-Based Designer Biologics (FBDB™) is a trademark owned by HanchorBio (www.hanchorbio.com).



Our proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with multi-targeting modalities to unleash both innate and adaptive immunity

HanchorBio Inc. 漢康生技股份有限公司 ▮ +8862-27921366 ▮ hanchorbio_tw@hanchorbio.com
5F-1, No. 1, Sec. 1, Tiding Blvd., Neihu Dist., Taipei City 114, Taiwan ▮ www.hanchorbio.com

ATON

Aton Biotech, a wholly-owned subsidiary of Henlius, is a fast-growing **CDMO** committed to enabling new biological drugs for clients with integrated bio-pharmaceutical platform. Our service ranges from cell line development to clinical and end-to-end CDMO commercial manufacturing services, including development of mammalian expressed monoclonal antibodies, fusion proteins, bispecific antibodies, ADC, etc. In addition to the industry-leading manufacturing technology platforms, Aton Biotech has established an international level team, with high-quality talent reserve and robust team structure. The core management team has more than 15 years of senior management and industry experience.

Henlius now have two commerical operated facilities, Xuhui Facility and Songjiang First Plant, with a total capacity of 48,000L. Meanwhile, Henlius started construction of Songjiang Second Plant in 2019. The first phase of the project is planned to have a total capacity of 96,000L, of which 36,000L is expected to be put into commercial operation by the end of 2024.

Henlius will rationally allocate and maximize utilization of capacity and technology. The plan is to allocate **24,000L** of Xuhui Facility to Aton Biotech at the end of 2024, which will further accelerate Aton Biotech' s global GMP standard manufacturing capacity, enable Aton Biotech to realize efficient connection from early clinical to commercial manufacturing, and strive to meet the needs of global customers and improve the project delivery capability with experienced manufacturing and quality team.

100+ Technical staff,experienced management team

30+ Molecules (mAb,BsAb,fusion protein , ADC,etc)

50+ IND approved (China,USA,etc.)

100% Technology transfer success rate

100+ Tox & clinical batches

450+ Commercial batches

OUR SERVICES





About Henlius

Henlius (2696.HK) is parent company of Aton Biotech, which is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practices (GMPs).

86-021-33395966
BD@atonbio.com
www.atonbio.com
Aton (Shanghai) Biotech Co., Ltd.
1289 Yishan Road, Xuhui District, Shanghai, China



HANHAI BIOLABS

Wuxi Huishan life science and Technology Industrial Park
无锡惠山生命园

Wuxi Huishan life science and Technology Industrial Park -- a domestic first-class "Chinese biological Valley" synchronized with the world.

It builds an innovation and entrepreneurship incubation service system integrating "R & D incubation industrialization", initially form three leading industries: advanced medical devices, high-end biomedicine and cutting-edge precision medicine, and build core platforms such as Beijing Genomics Institute of Chinese Academy of Sciences, Wuxi Research Institute, national biological testing platform for small and medium-sized enterprises, casi high-end generic drug R & D and production base.

Wuxi Huishan life science and Technology Industrial Park supports the development and growth of enterprises through financial subsidy policies, scientific and financial policies, preferential policies for talents, preferential policies for office space, whole-process support and project implementation assistance.

Hanhai Bio

Headquartered in Silicon Valley, Hanhai BioLabs started the journey in 2012, with a mission to promote interaction among global innovation resources and being a global leader in life-science investment, incubation and acceleration. Hanhai Biolabs is aiming to connect the premier healthcare startups with industry-led investors, mentors, and corporate partners around the world in order to build a healthcare innovation ecosystem. It is focusing on the early-stage Biotech , MedTech and Device startups. In addition to its investment arm, Hanahai Biolabs has designed a 3-month acceleration program to fund and mentor young leaders creating the solutions for a sustainable and accessible healthcare future. Companies in the program will have access to world-leading physicians, researchers, professionals, and executives. Accelerator participants also have access to specialized workspaces in South San Francisco, San Jose and Los Angeles, networking events, and the potential for the initial capital injection provided by the funding partners.



Q BAY COWORKING SPACE

We are located in the heart of Silicon Valley in San Jose with very easy access to public transportation and highways, neighboring high-tech giants like Samsung, Intel, and Cisco.

We provide a variety of coworking space options including hot desks, dedicated desks, and a plus for remote workers, freelancers, and startups. All our members have access to the modern conference rooms, shared cafeteria, collaboration areas, phone booths, gym, and outdoor leisure areas.

Beyond the space, we also support your business with customized acceleration plans, global industrial resources, mentorships, and a diversity of community events.

STARTS FROM $ 150 / month



Limited-time promotion program is on!

PRICE	HOT DESK	DEDICATED DESK	DEDICATED DESK PLUS
Monthly	$150	$400	$600
Half-yearly (10% off)	$810 ($135/mon)	$2160 ($360/mon)	$3240 ($540/mon)
Yearly (15% off)	$1530 ($127.5/mon)	$4080 ($340/mon)	$6480 ($510/mon)
Referral Reward	Q Bay Community members who successfully refer a contract (not less than 3 months) will be given a $100 gift card!		

Scan to book a tour or reach us at: info@qbay.com

Q BAY TRAINING CENTER

Bay Training Center is well equipped with an LED screen, lighting system, and audio equipment as well as movable desks and chairs. It can accommodate up to 200 people for events like roadshows, startup competitions, conferences, seminars, training, and other activities.

Venue Highlights:

- 20% off for Q Bay community companies
- 20% off workday, 10% off non-workday
- Cash referral reward
- Professional lighting and sound system
- Customized service for multilevel needs
- Leisure area with non-workday rental
- Easy transportation and parking

Scan to book 〉 〈 Pricing inside



Starts from:
$800



康龙化成 PHARMARON

www.pharmaron.com

PHARMARON is a leading, fully integrated pharmaceutical R&D services platform with global operations and has a well-established team of over 19,000 employees working in 20 different sites located in China, US and UK. Our mission is to support our partners' success in discovery, development and commercialization of innovative medicines.

Laboratory Services

- Synthetic Chemistry & Medicinal Chemistry
- Analytical Chemistry
- Computational Chem. & CADD
- DMPK/ADME
- Biology & Pharmacology
- Medical Device Evaluation
- Safety Assessment

Chemistry, Manufacturing and Control

- Process Chemistry & Analytical Dev.
- Material Science
- GMP API Manufacturing
- Formulation Development
- Drug Product Manufacturing
- Commercial-scale Manufacturing

Clinical Development

- Radiolabelled Chemical Synthesis
- Clinical Bioanalysis (GCP)
- Radiolabelled Science
- Clinical Pharmacology (US-based)
- Clinical Development (China-based)
- Clinical SMO (China-based)

Biologics & CGT

- Discovery Biologics
- Biologics CDMO
- CGT Lab Services
- CGT CDMO

康龙化成 PHARMARON

JOB OPENINGS

- Senior Programmer
- Clinical Data Coordinator
- Senior Clinical Data Manager
- Principal Statistical Programmer
- Statistical Programmer
- Senior Statistician
- Statistician
- Senior) Account Manager (Maryland/New Jersey)
- (Senior) Director, Business Development (California)
- QA manager
- IT manager

PHARMARON CLINICAL is one of the world's most trusted and respected CROs. Our core team is comprised of highly motivated CRO and pharmaceutical industry veterans who collaborate to offer their diverse experience in domestic and global clinical trials.

EMPLOYEES	CLINICAL TRIALS SUCCESSFULLY COMPLETED IN THE PAST 4 YEARS	YEARS OF CORE TEAM EXPERIENCE	GLOBAL OFFICE BRANCHES, SERVING CHINA, THE UNITED STATES, KOREA, AND JAPAN	CLIENTS WORLDWIDE
3500+	300+	15+	16+	200+

PHARMARON CLINICAL

www.pharmaron.com

BIORTUS

Your Protein-Focused Partner in Drug Discovery

BIORTUS CryoEM 冷冻电镜国际创新中心

Wuxi Biortus Biosciences Co. Ltd., is an **innovation-driven** contract research organization (CRO) **specializing in structure-based drug discovery (SBDD)**. Since 2009, we've partnered worldwide with numerous research institutions, pharmaceutical, and biotech companies. Our headquarters is based in Jiangyin with branch sites in Wuxi, Shanghai, and Boston, MA.

- Biortus is the **first and largest commercial cryo-EM service provider** in China with 8 microscopes, 3 of which are the newest Titan Krios G4's.
- Our **gene-to-lead platform** provides **modular services** in target protein production, *in vitro* assay development, fragment and compound library screening, and structure determination to assist SAR for lead optimization.

For more information, please visit us at https://en.wuxibiortus.com or contact Dr. Lei Jin via lei.jin@wuxibiortus.com



RNA and ligand-bound



Resolved PROTAC

Fab:Protein Complex



GPCRs

XT-THRIVE®

DMSO-FREE & HIGH-PERFORMANCE
CELL & TISSUE CRYOPRESERVATION SOLUTION

X-Therma Inc., 2600 Hilltop Drive, Suite B220, Richmond, CA 94806
partnering@x-therma.com | www.x-therma.com

X-THERMA

Non-Toxic Choice with Uncompromised Performance



Chemically Defined
DMSO-, Serum- & Protein-Free
C&GT Scale-up Friendly
Plug & Play Integration
cGMP Grade with DMF Filing
Validated in Array of Therapeutic Cells
Made in USA

*** Image: Power of the science revealed under polarized light**
2nd place in National NanoArt contest, 2019
top: Water; middle: XT-ViVo®; bottom: AFPIII

PORTON ADVANCED

End-to-End Cell & Gene Therapy CDMO Services

At Porton Advanced Solutions, we are committed to accelerating delivery of life-changing advanced therapies to patients. As a Cell and Gene Therapy CDMO, we provide end-to-end biopharma solutions and services to our clients throughout the development and commercialization of their therapeutics.

Our goal is to improve availability and commercial viability of these life-changing treatments by accelerating therapeutic development through our unique, innovative approach.

Platforms

Cell Therapy	Viral Vectors	mRNA	Oncolytic Virus	Plasmid
Autologous, Allogeneic	AAVs, Lentivirus	mRNA drug substance Formulated drug product	AdV, VSV, HSV, Vaccinia Virus	Supercoiled plasmid Linear Plasmid DNA Vaccine

Services

Process Development	Analytical Development	cGMP Manufacturing	Testing Services	Licenses & Discovery research

Ascendas Park Campus
PD Lab and GMP Facility, 43,000 ft²

Sangtiandao Campus
GMP Facility, 170,000 ft²



Cranburry Campus
PD Lab, 20,824 ft²

- A total capacity of over 220,000 ft² for advanced therapy development and manufacturing.
- 10 state-of-the-art GMP production suites for Viral vector
- 10 state-of-the-art GMP production suites for Cell Therapy
- Hundreds of Classified Clean Rooms
- Aseptic system with liquid and lyophilization fills

Porton Advanced Solutions Ltd.
6 Cedarbrook Dr, Cranbury Township, NJ 08512

Contact us
(844) 576 7866
RFQ@portonadvanced.com

mRNA-LNP Products & Services

For Vaccine and Immunotherapy Development



mRNA-LNP Formulation

Antibody Engineering



CAR-T/NK Development

Antibody Services

- Monoclonal Ab Development
- Hybridoma Sequencing
- Human Antibody Screening
- Antibody Humanization
- Bispecific Antibody Engineering
- Stable Cell Line Generation

mRNA-LNP Services

- mRNA Design and Synthesis (IVT)
- mRNA Capping & Purification
- mRNA-LNP Encapsulation
- mRNA-LNP Scale Up and QC
- mRNA-LNP Validation In Vivo
- Ionizable Lipid Licensing

Immune Cell Services

- Lentivirus Production GMP
- CAR-T/NK Cell Generation
- CAR-T/NK Animal Model
- Immune Cell Engineering
- T/B/NK/Dendritic cell, Macrophages
- TCR knockout by CRISPR

All products are for research use only

Discover more | www.promab.com

ProMab Biotechnologies, Inc.
2600 Hilltop Dr, Building B, Suite C320, Richmond, CA 94806
1.866.339.0871 | info@promab.com
SCAN ME

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY (CABS)

For more information please visit:

Website: *www.cabsweb.org*

Mailing Address: 268 Bush Street, #1888, San Francisco, CA 94104, USA

General information: *Info@CABSweb.org*

Membership: *Membership@CABSweb.org*

Fundraising: *Fundraising@CABSweb.org*